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PREFACE 
 
 
 
Vascular smooth muscle cells (VSMCs) are the major type of cell content in the media of 
vasculature and are essential for maintaining vascular homeostasis. One distinct feature of 
VSMCs is phenotypic plasticity or phenotypic modulation: VSMCs can bear a spectrum of 
phenotypes from contractile form to synthetic form or to pro-inflammatory form or to 
osteochondrogenic form. The phenotypic modulation of VSMCs is associated with a diversity of 
vascular disorders and participates in the arterial pathogenesis. 
 
One characteristic of VSMC phenotypic modulation is the downregulation of contractile 
cytoskeletal proteins such as smooth muscle α actin, myosin heavy chain and SM22. This 
phenomenon is conventionally viewed as a passive outcome of arterial diseases until recently. In 
this project, we focused research on SM22, one of the contractile cytoskeletal proteins, and used 
Sm22 disruption in vivo and in vitro as a probe attempting to answer the question whether 
downregulation of contractile cytoskeletal proteins plays active roles in arterial pathogenesis 
such as inflammation and osteochondrogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 iv
TABLE OF CONTENTS 
 
Acknowledgments ------------------------------------------------------------------------------------------- ii 
Preface -------------------------------------------------------------------------------------------------------- iv 
List of Tables ------------------------------------------------------------------------------------------------ vi 
List of Figures ---------------------------------------------------------------------------------------------- vii 
Background --------------------------------------------------------------------------------------------------- 1 
Part I. Disruption of Sm22 promotes arterial inflammation -------------------------------------------- 5 
1. Introduction  ---------------------------------------------------------------------------------------- 5 
2. Materials and methods ---------------------------------------------------------------------------- 5 
3. Results --------------------------------------------------------------------------------------------- 11 
   3.1. Sm22-/- mice developed higher inflammatory responses upon arterial injury ------- 11 
   3.2. The pro-inflammatory environment in injured carotid arteries of Sm22-/- mice --- 14 
   3.3. The contributions of VSMCs to arterial inflammation after disruption of Sm22 --- 21 
4. Discussion ----------------------------------------------------------------------------------------- 25 
Part II. Disruption of Sm22 promotes arterial chondrogenesis --------------------------------------- 27 
1. Introduction --------------------------------------------------------------------------------------- 27 
2. Materials and methods  -------------------------------------------------------------------------- 27 
3. Results --------------------------------------------------------------------------------------------- 33 
   3.1. Enhanced medial chondrogenesis with compromised myogenesis in Sm22-/- mice   
         after carotid injury  --------------------------------------------------------------------------- 33 
   3.2. A transcriptional shift from myogenic to chondrogenic pattern in primary Sm22-/-  
           VSMCs and after Sm22 knockdown in a VSMC line ---------------------------------- 42 
 v
   3.3. Altered cell morphology after Sm22 disruption  ----------------------------------------- 45 
4. Discussion ----------------------------------------------------------------------------------------- 49 
Part III. Reactive oxygen species (ROS) mediated NF-κB activation after Sm22 disruption   
             couples pro-inflammatory and chondrogenic phenotypes of VSMCs --------------------- 52 
1. Introduction --------------------------------------------------------------------------------------- 52 
2. Materials and methods  -------------------------------------------------------------------------- 53 
3. Results --------------------------------------------------------------------------------------------- 56 
   3.1. NF-κB pathways were highly activated in injured carotid arteries of Sm22-/- mice -56 
   3.2. NF-κB pathways were activated after Sm22 knockdown and contributed to  
          pro-inflammatory gene expression -------------------------------------------------------- 59 
   3.3. NF-κB activation after Sm22 knockdown contributed to Sox9 induction ------------ 63 
   3.4. Boosted ROS production after Sm22 knockdown contributed to NF-κB activation  
          and induction of pro-inflammatory genes ------------------------------------------------ 64 
   3.5. ROS production after Sm22 knockdown induced pro-inflammatory genes --------- 68 
   3.6. ROS production after Sm22 knockdown induced Sox9 expression ------------------- 69 
   3.7. ROS produced by both mitochondria and NADPH oxidase might be facilitated by 
          disorganized cytoskeleton in the absence of Sm22  ------------------------------------- 70 
4. Discussion ----------------------------------------------------------------------------------------- 75 
Appendix  ---------------------------------------------------------------------------------------------------- 82 
References --------------------------------------------------------------------------------------------------- 84 
Abstract ------------------------------------------------------------------------------------------------------ 97 
Autobiographical Statement  ------------------------------------------------------------------------------ 99 
 
 vi
LIST OF TABLES 
 
Table 1. Sm22 siRNA sequences ------------------------------------------------------------------------- 8 
Table 2. List of primers for rtRT-PCR in inflammation ----------------------------------------------- 9  
Table 3. List of primers for rtRT-PCR in chondrogenesis ------------------------------------------- 30  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii
LIST OF FIGURES 
 
Figure 1. Enhanced inflammatory responses of Sm22-/- mice after artery injury  ----------------- 12 
Figure 2. Prominent inflammatory cell infiltration in Sm22-/- mice after artery injury ----------- 13 
Figure 3. High expression of adhesion molecules in Sm22-/- mice after artery injury ------------ 16 
Figure 4. Higher expression of chemokines in Sm22-/- mice after artery injury ------------------- 18 
Figure 5. Higher induction of Ptgs2 in Sm22-/- mice after artery injury ---------------------------- 20 
Figure 6. Transcriptional upregulation of pro-inflammatory genes in primary Sm22-/- VSMCs  
                 and in PAC1 cells after Sm22 knockdown ------------------------------------------------- 22 
Figure 7. Induction of pro-inflammatory genes by Sm22 siRNAs in PAC1 cells and inhibition  
                of pro-inflammatory genes in primary Sm22-/- VSMCs by Sm22 overexpression  ---- 24 
Figure 8. Enhanced expression of type II collagen in Sm22-/- mice after artery injury ----------- 34 
Figure 9. Chondrocytic morphology of media in Sm22-/- mice after artery injury ---------------- 36 
Figure 10. Augmented expression of aggrecan and Bmp2 in Sm22-/- mice after artery injury -- 37 
Figure 11. Augmented expression of osteopontin in Sm22-/- mice after artery injury ------------ 38 
Figure 12. Augmented expression of Sox9 in Sm22-/- mice after artery injury -------------------- 40 
Figure 13. Lower expression of Acta2 in Sm22-/- mice after artery injury ------------------------- 41 
Figure 14. Chondrogenic switch of VSMCs in primary Sm22-/- VSMCs and in PAC1 cells  
                  after Sm22 knockdown ----------------------------------------------------------------------- 43 
Figure 15. Altered morphology in primary Sm22-/- VSMCs and in PAC1 cells after Sm22  
                   knockdown  ----------------------------------------------------------------------------------- 46 
Figure 16. Activation of NF-κB pathway in Sm22-/- mice 2 weeks after artery injury ----------- 58 
Figure 17. Nuclear expression of NF-κB subunits in primary Sm22-/- VSMCs ------------------- 59 
Figure 18. Sm22 knockdown activated NF-κB pathways -------------------------------------------- 60 
Figure 19. NF-κB inhibitor Bay-11-7082 blocked induction of pro-inflammatory genes after  
                  Sm22 knockdown ----------------------------------------------------------------------------- 61 
 viii
Figure 20. NF-κB inhibitor IMD-0354 blocked induction of pro-inflammatory genes after  
                   Sm22 knockdown  ---------------------------------------------------------------------------- 62 
Figure 21. NF-κB inhibitors blocked induction of Sox9 after Sm22 knockdown ----------------- 63 
Figure 22. Elevated ROS production after Sm22 disruption ----------------------------------------- 65 
Figure 23. Elevated ROS production after Sm22 disruption contributed to NF-κB activation -- 67 
Figure 24. Elevated ROS production after Sm22 disruption induced activation of  
                  pro-inflammatory genes ---------------------------------------------------------------------- 68 
Figure 25. Elevated ROS production induced Sox9 expression after Sm22 knockdown --------- 69   
Figure 26. Induction of Sod2 after Sm22 disruption   ------------------------------------------------- 71 
Figure 27. Altered mitochondria organization after Sm22 disruption   ----------------------------- 72 
Figure 28. Activation of NADPH oxidase after Sm22 disruption ----------------------------------- 73 
Figure 29. Altered microtube organization after Sm22 disruption ---------------------------------- 74 
Figure 30. A working model illustrating phenotypic modulation of VSMCs and arterial  
                  pathogenesis after Sm22 disruption  -------------------------------------------------------- 79 
 
 
 
 
 
 
 
 
 
  
1
BACKGROUND 
 
B1. Phenotypic modulation of vascular smooth muscle cells (VSMCs) and pathogenesis of 
vascular disorders 
VSMCs are the major cell type residing in the medial layer of arteries and veins. 
Interweaved with the medial extracellular matrix (ECM), VSMCs are essential for medial 
structure by synthesizing and organizing ECM proteins such as elastin and collagen; meanwhile, 
VSMCs control contraction/dilation of vessels to regulate blood pressure and tissue blood flow. 
VSMCs are classically known to bear two phenotypes: contractile form and synthetic form 1-3. 
The contractile phenotype, also known as differentiated phenotype, is characterized by the 
presence of distinct contractile and motile apparatus in subcellular domains such as abundant 
stress fibers and high expression of contractile apparatus proteins such as smooth muscle α actin 
(ACTA2), myosin and calponin, and this is the typical physiological phenotype of VSMCs. The 
synthetic phenotype, also known as “dedifferentiated phenotype”, on the other hand, is featured 
by low expression of contractile proteins, increased expression of other cytoskeletal proteins 
such as vimentin and loss of subcellular organization of contractile apparatus, and this phenotype 
of VSMCs is mostly present in vascular diseases 1-4. A variety of stimuli including platelet-
derived growth factor can drive VSMCs from the differentiated contractile phenotype to the 
dedifferentiated synthetic phenotype 2, 4. Accumulating research based on clinical samples and 
animal models of vascular diseases further characterizes the dedifferentiated phenotypes of 
VSMCs under various pathological conditions such as arterial atherosclerosis 5, 6, arteriopathy of 
diabetes and chronic kidney diseases 3, 7, 8. These phenotypes include but are not limited to pro-
inflammatory 6, 9, osteogenic 3, 10, osteochondrogenic 3, 10 and adipogenic phenotypes 3. The 
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diversity of VSMC phenotypes in vascular diseases highlighted the plasticity of VSMCs and its 
potential active contribution to pathogenesis of vascular disorders.  
 
Current studies on phenotypic modulation of VSMCs focus on extracellular stimuli such 
as cytokines 2, 11, lipids 12, 13, advanced glycation end products 14, 15 and hemodynamic alterations 
6, 9, while the loss of contractile phenotype and corresponding proteins such as ACTA2 and 
SM22 is generally considered as a passive outcome instead of an active driving force in 
phenotypic modulation hence pathogenesis. However, research from independent groups 
revealed that downregulation of contractile proteins is an early event of pathogenesis of vascular 
disorders and phenotypic modulation 16, 17, which suggests that loss of contractile proteins may 
actively drive the overall phenotypic modulation. To further explore the putative active role of 
contractile proteins in VSMC phenotypic modulation during vascular pathogenesis, we used 
SM22, a VSMC marker contractile protein, as a probe by investigating the distinct responses of 
Sm22 knockout mice (Sm22-/-) to carotid artery denudation, an arterial injury model 18. 
 
B2. Expression of Sm22 is downregulated in arterial diseases 
SM22, also known as SM22α or transgelin, is a 22 kDa protein abundant in smooth 
muscle cells (SMCs) of vertebrates 19, 20. It belongs to calponin family since it contains an N-
terminal calponin homology domain and a C-terminal calponin-like domain 21, 22. The C-terminal 
calponin-like domain is necessary for actin affinity and the actin-binding activity of SM22 is 
independent of calcium 22. The basic molecular function of SM22 is to bind actin and participate 
in formation of cytoskeletal structure such as stress fiber 21, 22 and podosome 23. SM22 has been 
widely used as an SMC marker during embryogenesis and in adulthood 24. SM22 transcription 
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denotes the onset of cardiovascular system and SMC formation during embryogenesis 25, 26. 
Evidence from Sm22 knockout mice indicates that Sm22 is required in modulating contractility 
of SMCs 27, 28. Recent studies reveal that Sm22 also participate in regulation of cell proliferation 
29 and apoptosis 30. 
 
SM22 may play a role in the pathogenesis of a variety of human diseases. Expression of 
SM22 is decreased in several cancers including breast cancer 31, prostate cancer 32 and colon 
carcinoma 31, 33, indicating SM22’s role in cancer progression. More interestingly, expression of 
SM22 is also down-regulated in atherosclerotic coronary arteries 34, thoracic16 aortic aneurysms 
and abdominal aortic aneurysms 35. In mouse atherosclerosis model, transcription of Sm22 
decreased in atherosclerotic plaques of apolipoprotein E knockout (ApoE -/-) mice 36. These data 
strongly suggest that SM22 may be involved in pathogenesis of such arterial diseases as 
atherosclerosis. However, Sm22-/- mice are fertile with uncompromised vasculature development 
and morphology, normal blood pressure and heart rate 26. This suggests that Sm22 may be 
functionally compensated during vasculature development and that it may be required in arterial 
stress response instead of homeostasis 26. Indeed, disruption of Sm22 in ApoE -/- mice lead to 
enlarged atherosclerotic lesions 37.  
 
These results indicate that loss of Sm22 might independently promote arterial 
pathogenesis. Arterial inflammation and osteochondrogenesis are two common features of 
arterial diseases; meanwhile, pro-inflammatory VSMCs and osteochondrogenic VSMCs have 
emerged as two key phenotypes of VSMC phenotypic modulation. Therefore, it is reasonable to 
link SM22, as a VSMC marker, to these two VSMC phenotypes and arterial inflammation and 
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osteochondrogenesis in arterial disorders. To test the hypothesis that SM22 actively participate in 
arterial pathogenesis, inflammation and osteochondrogenesis in particular, we generated Sm22 -/- 
mice 38 and performed carotid artery denudation, an arterial injury model 18, followed by 
histological and molecular analyses of carotid artery samples. We also conducted corresponding 
investigation on primary Sm22-/- VSMCs as well as in PAC1 cell, a VSMC cell line 39, after 
Sm22 knockdown. 
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PART I 
Disruption Of Sm22 Promotes Arterial Inflammation 
 
1. Introduction 
Loss of Sm22 in ApoE -/- mice led to enlarged atherosclerotic lesions with prominent 
macrophage infiltration, a sign of enhanced inflammation 37. It is well documented that 
inflammation is involved in development of atherosclerosis 40-43. However, what are the 
mechanisms underlying the augmented inflammatory response in Sm22-/-ApoE-/- mice? 
Inflammation is also involved in other arterial diseases such as hypertension 44, 45, abdominal 
aortic aneurysms 46, diabetic arteriopathy 44, 45 and chronic kidney disease (CKD) 47. Is pro-
inflammation an intrinsic feature after loss of Sm22? To answer these questions in arterial injury 
responses, we challenged Sm22 knockout mice using an arterial injury model, carotid artery 
denudation 18. 
 
2. Materials and Methods 
2.1. Artery injury by carotid artery denudation.  
The mouse carotid artery denudation protocol was approved by the Animal Investigation 
Committee at Wayne State University. Sm22-/- mice and their Sm22+/+ littermates on a mixed 
C57BL6 x SV129 genetic background were used. Carotid artery denudation was carried out on 
male Sm22-/- mice and their wild type littermates of 18–20 weeks of age, as described 18. Briefly, 
Sm22-/- mice and their Sm22+/+ littermates were subjected to surgery. After anesthesia of mice 
using 2% avertin intraperitoneally (0.25 mg/g body weight),  a curved guide wire of 0.35 mm in 
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diameter was introduced into the left common carotid and passed in and out of the left common 
carotid with constant rotation for three passages. Two weeks after surgery, the mice were 
sacrificed and both carotid arteries were harvested. Five Sm22-/- mice and their Sm22+/+ 
littermates were used for histological and immunohistochemical analyses. The carotid segments 
of 3 mm in length covering the part from 2 mm to 5 mm proximal to the carotid bifurcation were 
harvested and embedded in OCT medium (Tissue-Tek), and around 100 frozen slides were made 
for each mouse with triplicate sections on each slide at 8 µm thickness. Five Sm22-/- mice and 
their Sm22+/+ littermates were used for real-time RT-PCR: the carotid arteries of these mice were 
stored separately in RNAlater reagent (Ambion) at 4°C for no more than 1 week before RNA 
extraction.  
 
2.2. Immunohistochemical (IHC) analyses. 
Six slides, in the order of one every 15 consecutive slides, from each mouse were used 
for Hematoxylin and eosin (H&E) staining to screen sections with most prominent inflammatory 
responses. IHC was performed on the properly selected consecutive frozen slides using 
VECTASTAIN Elite ABC Kit (Vectorlabs). Briefly, air-dried slides were fixed in methanol 
containing 0.3% H2O2 for 10 minutes and blocked with serum for 20 minutes. The following 
incubation steps of primary antibody, secondary antibody, ABC reagent and DAB substrate were 
performed according to the manufacturer’s protocol. The slides were counterstained with 
hematoxylin. The primary antibodies (1:50 dilution) were against F4/80 (Abcam, ab6640), CD3 
(Abcam, ab5690), PTGS2 (Santa Cruz, sc-1747), CX3CL1 (Abcam, ab25088), CCL2 (Abcam, 
ab7202), VCAM1 (Santa Cruz, sc-1504), ICAM1 (Santa Cruz, sc-1511), SPP1 (Santa Cruz, sc-
10593).  
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2.3. Morphometric analysis 
For each antibody, both 100X and 400X images were taken using a Leica DM4000B 
microscope (Leica). Images of adventitia and media were separated using Photoshop 7.0 
software. Semi-quantitative analyses of positive signals in adventitia and media were performed 
on all 100X images using color segmentation and integrative optical density function in the 
Image-Pro software (Media Cybernetics).  
 
2.4. Primary VSMC culture. 
VSMCs were isolated from aortas of six Sm22-/- mice and six Sm22+/+ mice as described 
48. Primary VSMCs were kept in the DMEM medium (Invitrogen) containing 10% fetal bovine 
serum (FBS) (Invitrogen) and passed upon confluency at a 1:2 dilution ratio. Primary VSMCs in 
passage 2 to passage 4 were used for experiments. 
 
2.5. Transfection of primary VSMCs 
Primary Sm22-/- VSMCs at 80% confluency in a 12-well plate were transfected with the 
pcDNA3_Sm22 expression plasmids or the pcDNA3 vectors using the Lipofectamine and Plus 
reagents (Invitrogen). Cells were harvested for mRNA extraction two days after transfection 
when confluency was reached. 
  
2.6. Sm22 knockdown in PAC1 cells with siRNA.  
Sm22 knockdown was achieved using Dicer-Substrate siRNA duplexes (IDT, 
MMC.RNAI.N011526.5.1, siA in Table 1). PAC1 cells 39 (a pulmonary arterial SMC cell line) 
were seeded at 30% confluency 24 hours before transfection. Transfection was performed using 
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DharmaFECT3 (Dharmacon) with siRNA duplex or scrambled RNA duplex at 100 nM, and the 
FBS was diluted to 2% with media 24 hours after transfection for optimal cell density. In parallel 
experiments, the following small molecules were added respectively 24 hours after transfection: 
NF-κB inhibitors, Bay-11-7082 (10 μM) and IMD-0354 (200 nM); ROS scavengers, Tiron (5 
mM), Tempol (1 mM) and NAC (5 mM); NADPH oxidase and mitochondria complex I inhibitor, 
DPI (5 μM). Cells were used for experiments 72 hours after transfection unless otherwise 
specified. Two other siRNA duplexes (IDT, MMC.RNAI.N011526.5.2, designated as siC and 
IDT, MMC.RNAI.N011526.5.3, designated as siB in Table 1) were also used independently at 
200 nM concentration to rule out off-target effects of the siRNAs. 
siA nt sequence 
MMC.RNAI.N011526.5.1-S1 25 rGrCrArGrArUrCrArUrCrArGrUrUrArGrArArArGrGrGrAAG 
MMC.RNAI.N011526.5.1-A1 27 rCrUrUrCrCrCrUrUrUrCrUrArArCrUrGrArUrGrArUrCrUrGrCrCrG 
siB   
MMC.RNAI.N011526.5.3-S1 25 rGrGrArGrCrArUrArArGrArGrGrGrArCrUrUrCrArCrArGAC 
MMC.RNAI.N011526.5.3-A1 27 rGrUrCrUrGrUrGrArArGrUrCrCrCrUrCrUrUrArUrGrCrUrCrCrUrG 
siC   
MMC.RNAI.N011526.5.2-S1 25 rCrCrArGrUrCrCrArCrArArArCrGrArCrCrArArGrCrCrUTC 
MMC.RNAI.N011526.5.2-A1 27 rGrArArGrGrCrUrUrGrGrUrCrGrUrUrUrGrUrGrGrArCrUrGrGrArA 
Table 1. Sm22 siRNA sequences. 
 
2.7. Real-time RT-PCR (rtRT-PCR).  
Total RNA from carotid arteries was extracted and purified using RNeasy Fibrous Tissue 
Kit (Qiagen), and total RNA from primary VSMCs or PAC1 cells was extracted and purified 
using RNeasy Kit (Qiagen). The cDNA was synthesized using the Superscript II reverse 
transcriptase (Invitrogen). Real-time PCR was performed using SYBR Green on a StepOnePlus 
system (Applied Biosystems). Gapdh and snRNA U6 were used as internal controls in ΔΔCt 
method. All PCR primers were designed to cover at least 2 exons (Table 2). 
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Gene Forward (5' - 3') Reverse (5' - 3') Size (bp) 
Ccl2    
Mouse CAGTTAACGCCCCACTCAC GGTTCTGATCTCATTTGGTTCC 217 
Rat CAGTTAATGCCCCACTCAC GTTTCTGATCTCACTTGGTTCT 217 
Cx3cl1    
Mouse CCTCGGCATGACGAAATGCGAAAT TTTCTCCTTCGGGTCAGCACAGAA 163 
Rat CCTCGGCATGACGAAATGCAACAT TCTCCTTTGGGTCAGCACAGAAGT 161 
Gapdh    
Mouse TGAATACGGCTACAGCAACAGGGT TTGTGAGGGAGATGCTCAGTGTTG 151 
Rat same as mouse same as mouse 151 
Icam1    
Mouse AGTCCGCTGTGCTTTGAGAACTGT ACTCTCCGGAAACGAATACACGGT 60 
Rat ACAGCAGACCACTGTGCTTTGAGA ACTCGCTCTGGGAACGAATACACA 60 
Ptgs2    
Mouse GGCCATGGAGTGGACTTAAATC AAGGCGCAGTTTATGTTGTCTGT 66 
Rat same as mouse same as mouse 66 
Sm22    
Mouse TCCTTCCAGTCCACAAACGACCAA TTTGGACTGCACTTCTCGGCTCAT 92 
Rat TCCTTCCAGCCCACAAACGACCAA CTTGGACTGCACTTCACGGCTCAT 92 
Vcam1    
Mouse TGTGAAGGGATTAACGAGGCTGGA GCACATTTCCACAAGTGCAGGAGA 151 
Rat TGTGAAGGGATTAACGAGGCTGGA GCACACTTCCACAAGTACAGGAGA 151 
 Table 2. List of primer sequence for rtRT-PCR in inflammation. Tm = 60°C for all primers. 
 
2.8. Immunofluorescence (IF).  
PAC1 cells on chamber slides were fixed in methanol for 10 minutes at -20°C and 
blocked with 10% chicken serum for 30 minutes. Then, cells were incubated with primary 
antibodies at 1:100 dilution for 2 hours followed by incubation with Alexa Fluor chicken 
secondary antibodies at 1:200 dilution (Invitrogen) for 1 hour. Slides were mounted with 
Vectashield with DAPI (Vectorlabs) and examined on a Leica DM4000B microscope (Leica). 
Quantification was performed using Image-Pro software (Media Cybernetics). Primary 
antibodies were against SM22 (Abcam, ab14106), CCL2 (Santa Cruz, sc-1785). 
 
2.9. Preparation of cell lysates.  
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M-PER Mammalian Protein Extraction Reagent (Pierce) with Halt Protease Inhibitor 
Cocktail (Pierce) was used to prepare whole cell lysates from primary VSMCs and PAC1 cells. 
Cell lysates were stored at -20 °C. 
 
2.10. Western blotting.  
Equal amount of whole cell lysates, the nuclear fraction or cytoplasmic fraction from 
primary VSMCs or PAC1 cell samples were loaded on a 4-12% Bis-Tris NuPAGE Mini-gel 
(Invitrogen) for electrophoresis, followed by transfer onto an Immobilon-P membrane 
(Millipore). The membrane was blocked with 5% milk for 30 minutes, followed by primary 
antibody incubation overnight at 4 °C. After incubation with biotinlyated secondary antibody for 
30 minutes, the membrane was subject to enhanced chemiluminescence detection using 
SuperSignal West Pico Chemiluminescent Substrate (Pierce). The primary antibodies were 
against SM22 (1:1000, Abcam, ab14106), VCAM1 (1:100, Santa Cruz, sc-1504), and GAPDH 
(1:2500, Abcam, ab9485). 
 
2.11. Statistics.  
Five Sm22-/- mice and five Sm22+/+ littermates were used in histology, IHC and rtRT-
PCR analyses. Primary VSMCs from four Sm22-/- mice and four Sm22+/+ mice were used for 
rtRT-PCR analyses. Three independent experiments were performed in Sm22 knockdown 
research in PAC1 cells. Values are means ± SE. Statistical analyses were performed using 
SPSS13.0 software (IBM). Student t-test was applied to evaluate differences in all experiments 
and differences were considered significant at p < 0.05.  
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3. Results 
3.1. Sm22-/- mice developed higher inflammatory responses upon artery injury  
To determine the roles of Sm22 under pathological conditions, we performed carotid 
artery denudation using the Sm22-/- mice and their Sm22+/+ littermates. Before injury, the size of 
the media and adventitia for their carotid arteries are similar (Fig. 1A, B). 2 weeks after injury, 
we found that the injured carotid arteries from Sm22-/- mice swelled significantly more than those 
from Sm22+/+ mice. In addition, the response was similar between Sm22+/+ and Sm22+/- 
littermates (Fig. 1C). These carotid arteries adhered tightly to the surrounding tissues and were 
difficult to isolate. H&E staining showed thicker and fibrotic artery walls (Fig. 2A) with 
remarkable cell infiltration in the media and adventitia of the carotid arteries in Sm22-/- mice (Fig. 
2A). IHC using F4/80 (a macrophage specific marker) (Fig. 2B) and CD3 (a T lymphocyte 
marker) (Fig. 2C) revealed greater macrophage and T lymphocyte infiltration in the injured 
carotid arteries of Sm22-/- mice. These findings demonstrate enhanced inflammatory response of 
Sm22-/- mice upon artery injury. 
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Figure 1. Enhanced inflammatory responses in Sm22-/- mice 2 weeks after carotid artery 
denudation. (A) Quantitative analysis of carotid artery areas without and with injury. (B) 
Quantitative analysis of medial and adventitial areas of carotid arteries respectively. (C) H&E 
staining showed similar inflammatory responses of carotid arteries to denudation between 
Sm22+/+ mice and Sm22+/- littermates. Bar, 100 µm. Values (A, B) were means ± SE from five 
pairs of mice. The asterisk, *, indicates p < 0.05. 
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Figure 2. Prominent inflammatory cell infiltration in Sm22-/- mice 2 weeks after carotid 
artery denudation. (A) H&E staining showed pronounced carotid swelling, edema, prominent 
fibrotic adhesion and cell infiltration in denuded carotid arteries of Sm22-/- mice. Bar, 100 µm. (B, 
C) IHC using a macrophage marker, F4/80 (B) and a T cell marker, CD3 (C). Top panels, 100X; 
middle panels, 400X; bottom panels: quantification of positive signals from images at 100X 
magnification of carotid arteries from five Sm22-/- and their littermates Sm22+/+ mice. Values are 
means ± SE. The asterisk, *, indicates p < 0.05. Representative positive signals (brown) are 
indicated by arrows. Bars: upper panels, 100 µm; middle panels, 20 µm. Abbreviations: N, 
neointima; M, media; A, adventitia. 
 
3.2. The pro-inflammatory environment in injured carotid arteries of Sm22-/- mice 
To reveal the molecular mechanisms underlying the inflammation prone scenario in 
carotid arteries of Sm22-/- mice after injury, we investigated the expression of several major pro-
inflammatory molecules using rtRT-PCR in whole carotid arteries and IHC in the VSMC-rich 
media of carotid arteries. Cell adhesion molecules, including vascular cell adhesion molecule 1 
(VCAM1) and intercellular adhesion molecule 1 (ICAM1), contribute to arterial inflammation 
via retention of inflammatory cells such as macrophages and T lymphocytes in the inflammation 
sites 49. There was no significant difference between the two groups in mRNA expression of 
either adhesion molecule without injury (Fig. 3A, left panel); however, the injury induced change 
of Vcam1 mRNA expression was two times higher in Sm22-/- mice (Fig. 3A, right panel). IHC 
showed that expression of both Vcam1 (Fig. 3B) and Icam1 (Fig. 3C) in the media was five 
times higher in Sm22-/- mice.  
 
Chemokine (C-X3-C motif) ligand 1 (CX3CL1) and monocyte chemotactic protein-1 
(CCL2), two chemokines that potently recruit monocytes and T lymphocytes, participate in 
various arteriopathies 49. Both the basal level and injury induced change of Cx3cl1 mRNA 
appear to be higher in Sm22-/- mice (Fig. 4A, left panels), while no obvious difference was 
observed for Ccl2 (Fig. 4A, right panels). Protein expression of Cx3cl1 (Fig. 4B) in the media 
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was three times higher in Sm22-/- mice while the difference in Ccl2 (Fig. 4C) was not significant. 
Prostaglandin-endoperoxide synthase 2 (PTGS2), also known as cycloxygenase 2, is a 
characteristic inflammation marker since it mediates the synthesis of the vessel-active 
prostaglandin during inflammation 50. Despite similar transcriptional levels in the whole carotid 
arteries (Fig. 5A), Ptgs2 expression was two times higher in carotid media of Sm22-/- mice than in 
those of their Sm22+/+ littermates (Fig. 5B). These findings highlight a pro-inflammatory 
environment in injured carotid arteries of Sm22-/- mice where inflammatory cells were recruited, 
retained and activated.  
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Figure 3. Expression of cell adhesion molecules is higher in Sm22-/- mice 2 weeks after 
carotid artery denudation. (A) Relative mRNA level of Vcam1 and Icam1 in carotid arteries 
without injury (left panel) and expression level induced by injury (right panel) was evaluated 
using rtRT-PCR. (B, C) IHC analyses of Vcam1 (B) and Icam1 (C). Top panels, 100X; middle 
panels, 400X; bottom panels, quantification of positive signals at 100X magnification in the 
media of carotid arteries from five Sm22-/- and their littermates Sm22+/+ mice. Values (A, B and 
C) are means ± SE from five pairs of mice. The asterisk, *, indicates p < 0.05. Representative 
positive signals (brown) are indicated by arrows. Bars: top panels, 100 µm; middle panels, 20 
µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
19
Figure 4. Higher expression of chemokines in Sm22-/- mice 2 weeks after carotid artery 
denudation. (A) Left panel: relative mRNA expression of Cx3cl1 and Ccl2 in carotid arteries of 
mice without injury evaluated using rtRT-PCR. Right panel: “Injury induction fold”: the ratio 
between Cx3cl1 and Ccl2 mRNA expression in the injured carotid artery and the corresponding 
expression in the uninjured carotid artery of each mouse using rtRT-PCR. (B, C) IHC analyses 
of Cx3cl1 (B) and Ccl2 (C). Top panels, 100X; middle panels, 400X; bottom panels, 
quantification of positive signals in images at 100X magnification in the media of carotid arteries 
from five Sm22-/- and their littermates Sm22+/+ mice. Values (A, B and C) are means ± SE from 
five pairs of mice. The asterisk, *, indicates p < 0.05. Representative positive signals (brown) are 
indicated by the arrows. Bars: top panels, 100 µm; middle panels, 20 µm. 
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Figure 5. High induction of Ptgs2 in 
Sm22-/- mice 2 weeks after carotid 
artery denudation. (A) Relative 
mRNA expression of Ptgs2 in carotid 
arteries without injury (left panel) and 
injury induction level (right panel) 
was evaluated using rtRT-PCR. (B) 
IHC analyses of Ptgs2 in the media. 
Upper panels, 100X; middle panels, 
400X; lower panels, quantification of 
positive signals at 100X 
magnification in the media of carotid 
arteries from five Sm22-/- and their 
littermates Sm22+/+ mice. Values (A, 
B) were means ± SE from five pairs 
of mice. The asterisk, *, indicates p < 
0.05 versus Sm22+/+ mice. 
Representative positive signals 
(brown) are indicated by the arrows. 
Bars: upper panels, 100 µm; middle 
panels, 20 µm. 
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3.3 The contributions of VSMCs to arterial inflammation after disruption of Sm22 
Since the expression of the pro-inflammatory molecules was mainly located in the 
VSMC-rich artery media, we focused our efforts on analyzing VSMCs. We isolated VSMCs 
from aortas of both Sm22-/- and Sm22+/+ mice for primary culture. VSMCs from Sm22-/- mice 
expressed higher levels of Vcam1, Icam1, and Ccl2 (Fig. 6A). We also knocked down Sm22 in a 
VSMC line, PAC1 cells, using siRNA (Fig. 6B). As the Sm22 knockdown efficiency increased 
over time (Fig. 6B), the expression of the aforementioned pro-inflammatory molecules was 
gradually induced (Fig. 6B). Similarly, the extent of induction of Vcam1, Cx3cl1 and Ccl2 
appeared to correlate with Sm22 knockdown efficiency using three different siRNAs (Fig. 7A). 
Furthermore, to investigate if recapitulation of Sm22 could reverse the pro-inflammatory traits of 
VSMCs in the absence of Sm22, we re-introduced Sm22 into primary Sm22-/- VSMCs via 
plasmid transfection and observed 40-60% decrease in expression of Vcam1, Icam1, Cx3cl1 and 
Ccl2 (Fig. 7B). 
  
These observations highlight the intrinsic pro-inflammatory character of VSMCs after 
disruption of Sm22 expression and underscore the contributions of medial VSMCs to the 
enhanced arterial inflammatory responses upon injury in Sm22-/- mice. 
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Figure 6. Transcriptional upregulation of pro-inflammatory genes in primary Sm22-/- 
VSMCs and in PAC1 cells after Sm22 knockdown. (A) In primary Sm22-/- and Sm22+/+ 
VSMCs, relative mRNA expression of Vcam1, Icam1, Cx3cl1, Ccl2 and Ptgs2 was examined 
using rtRT-PCR and WB (inserted panel). Values are means ± SE from primary VSMCs of four 
pairs of mice. The asterisk, *, indicates p < 0.05. (B - C) In PAC1 cells, Sm22 knockdown 
efficiency and the expression of pro-inflammatory genes were determined by rtRT-PCR 1 day, 2 
days and 3 days after transfection and by WB (B, inserted panel) and IF (C) 3 days after 
transfection. Green: Sm22 and Ccl2; blue: DAPI.  Values in (B) are means ± SE from three 
independent experiments. The asterisk, *, indicates p < 0.05. Bar in (C): 20 µm. Abbreviations: 
scr, scrambled siRNA; si, Sm22 siRNA; d1/2/3, 1/2/3 days after transfection into PAC1 cells. 
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Figure 7. Induction of pro-inflammatory genes by Sm22 siRNAs in PAC1 cells and 
inhibition of pro-inflammatory gene expression in primary Sm22-/- VSMCs by Sm22 
overexpression. (A) Relative mRNA expression of Vcam1, Icam1, Cx3cl1 and Ccl2 by three 
different Sm22 siRNAs (siA, siB, and siC) was evaluated using rtRT-PCR. Values were means ± 
SE from three independent experiments. The asterisk, *, indicates p < 0.05. (B) Relative mRNA 
expression of Vcam1, Icam1, Cx3cl1, Ccl2 and Ptgs2 was evaluated using rtRT-PCR in primary 
Sm22-/- VSMCs after transfection with pcDNA3-Sm22 plasmids (SM22) or the control vector 
pcDNA3 (mock). Values were means ± SE. Abbreviations: scr, scrambled RNA; si, Sm22 
siRNA; Sm22-/-_mock, Sm22-/- primary VSMCS transfected with pcDNA3 plasmids; Sm22-/-
_SM22, Sm22-/- primary VSMCS transfected with pcDNA3-Sm22 plasmids. 
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4. Discussion 
Highly expressed in SMCs 19, 20, SM22 has been viewed as a SMC marker, especially in 
VSMCs. Several Sm22 Cre mice were generated and used in SMC specific conditional gene 
knockout 51, 52. Lack of vascular phenotypes in Sm22-/- mice implied that Sm22 might be required 
under stressed conditions of arteries 26. Studies show that SM22 may participate in pathogenesis 
of arterial diseases including atherosclerosis 34, 36, 37 and abdominal aortic aneurysm 35. In 
particular, the findings that Sm22-/-ApoE-/- mice exhibited more macrophage infiltration than 
Sm22+/+ApoE-/- mice in atherosclerotic plaques implying that Sm22 might be involved in 
inflammation of injured arteries 37. Inflammation is involved in multiple arteriopathies including 
atherosclerosis 40-43, hypertension 44, 45 and chronic kidney disease (CKD) 47. Therefore, it is 
worthwhile to look into the role of Sm22 in inflammation upon artery injury.  
 
The loss of functional compensation of Sm22 in diseased arteries highlights the 
molecular differences between the embryonic VSMC differentiation, artery homeostasis and 
phenotypic modulation of VSMCs 2, 10, 53-55 under arterial stresses. Proliferation and re-
differentiation is one of the features during VSMC phenotypic modulation in injured arteries, and 
this feature is common in cell culture system. So, we investigated events after Sm22 disruption 
using both in vivo injury model and in vitro VSMC culture system. 
 
Chronic arterial inflammation features infiltration of macrophages and T lymphocytes 
along with fibrosis in the artery wall 40, 43, 44, 56, 57. Several pro-inflammatory molecules are 
involved in the inflammatory status: chemokines such as CCL2 40, 43, 44, 49, 56 and CX3CL1 13, 49, 
adhesion molecules such as VCAM1 and ICAM1 13, 40, 43, 44, 56, 57. In addition, PTGS2 is also a 
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well known pro-inflammatory molecule in arterial diseases 50. Inflammation is one major event 
along with neointima formation in artery injury models such as carotid artery denudation, 
femoral denudation 58-62, and the inflammatory responses cover the whole artery wall from lumen 
to adventitia 58-61. Expression of Sm22 in artery adventitia after injury implied involvement of 
Sm22 in adventitial inflammatory responses 63. More macrophage and T lymphocyte infiltration 
in media and adventitia, excessive adventitial fibrosis and prominent thickening of denuded 
carotid arteries depicted higher inflammatory responses of arteries of Sm22-/- mice upon injury. 
The elevated expression of Ptgs2, Ccl2, Cx3cl1, Vcam1, and icam1 uncovered the existence of 
an injury-inducible pro-inflammatory molecular environment in arteries of Sm22-/- mice, and the 
discrepancy of induction between mRNA level and protein level might be due to post-
transcriptional modifications or increased stability of proteins. Since expression of pro-
inflammatory genes is finely regulated during inflammation 49, it is not surprising that changes in 
some pro-inflammatory genes such as Cxcl12 were not detected under the same conditions.  
 
In our system we only observed marginal neointima formation in injured carotid arteries: 
this might be due to the C57BL6 mice having mixed genetic background that may be resistant to 
injury-induced neointima formation 64-67. The dominant distribution of pro-inflammatory proteins 
in the VSMC-rich media suggests VSMCs as the cell sources for inflammation. Consistent with 
this notion, primary VSMCs from Sm22-/- mice and PAC1 after Sm22 knockdown also show 
upregulated expression of these pro-inflammatory genes. These results imply that disruption of 
Sm22 in VSMCs may independently establish a pro-inflammatory environment in the arteries 
under stressed conditions.  
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PART II 
Disruption Of Sm22 Promotes Arterial Chondrogenesis 
 
1. Introduction 
VSMCs have the capacity to undergo drastic phenotypic modulation from contractile and 
differentiated state to proliferative, dedifferentiated, chondrocytic and osteoblastic phenotypes in 
arterial diseases such as atherosclerosis and in vascular complications due to diabetes and CKD 7, 
8. Arterial chondrogenesis and osteogenesis lead to increased artery stiffness and compromised 
blood pressure regulation capacity, thus contributing to chronic heart failure 7, 8.  Medial VSMCs 
play essential roles in this process, as evidenced by the trans-differentiation of VSMCs to 
osteochondrocytic cells 8, 52, 68, 69. VSMC chondrogenic transdifferentiation features high 
expression of the key transcription factor SRY-box containing gene 9 (SOX9), syntheses and 
deposition of distinct extracellular matrix (ECM) proteins in the arterial media, such as type II 
collagen, aggrecan and osteopontin 7, 8, 52, 68. Expression of VSMC cytoskeleton proteins, 
including SM22, is down-regulated in the pathogenesis of arterial diseases and VSMCs exhibit 
distinct morphological changes 8, 34, 52, 68. In order to address the question of whether this 
downregulation of SM22 is just a passive outcome or an active pro-chondrogenic driving force, 
we analyzed the carotid arteries of Sm22 knockout mice after carotid artery denudation as wells 
as primary Sm22-/- VSMCs and PAC1 cells after Sm22 knockdown. 
 
2. Materials and Methods 
2.1. Artery injury by carotid artery denudation.  
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The mouse carotid artery denudation protocol was approved by the Animal Investigation 
Committee at Wayne State University. Sm22-/- mice on mixed C57BL6 and SV129 genetic 
background and their Sm22+/+ littermates were used. Carotid artery denudation was carried out on 
male Sm22-/- mice and their wild type littermates of 18–20 weeks of age, as described 18. Briefly, 
Sm22-/- mice and their Sm22+/+ littermates were subjected to surgery. After anesthesia of mice 
using 2% avertin intraperitoneally (0.25 mg/g body weight),  a curved guide wire of 0.35 mm in 
diameter was introduced into the left common carotid artery and passed in and out of the left 
common carotid artery with constant rotation for three passages. Two weeks after surgery, the 
mice were sacrificed and both carotid arteries were harvested. Five Sm22-/- mice and their 
Sm22+/+ littermates were used for histological and immunohistochemical analyses. The carotid 
segments of 3 mm in length covering the part from 2 mm to 5 mm proximal to the carotid 
bifurcation were harvested and embedded in OCT medium (Tissue-Tek), and around 100 frozen 
slides were made for each mouse with triplicate sections on each slide at 8 µm thickness. Five 
Sm22-/- mice and their Sm22+/+ littermates were used for rtRT-PCR: the carotid arteries of these 
mice were stored separately in RNAlater reagent (Ambion) at 4°C for no more than 1 week 
before RNA extraction.  
 
2.2. Immunohistochemical (IHC) analyses. 
Six slides, in the order of one every 15 consecutive slides, from each mouse were used 
for H&E staining to screen sections with most prominent inflammatory responses. IHC was 
performed on the properly selected consecutive frozen slides using VECTASTAIN Elite ABC 
Kit (Vectorlabs). Briefly, air-dried slides were fixed in methanol containing 0.3% H2O2 for 10 
minutes and blocked with serum for 20 minutes. The following incubation steps of primary 
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antibody, secondary antibody, ABC reagent and DAB substrate were performed according to the 
manufacturer’s protocol. The slides were counterstained with hematoxylin. The primary 
antibodies (1:50 dilution) were rabbit anti-type II collagen IgG (Abcam, ab53047), rabbit anti-
aggrecan (Santa Cruz, sc-25674), goat anti-SPP1 (Santa Cruz, sc-10593), rabbit anti-BMP2 
(Abcam, ab14933), rabbit anti-SOX9 (Abcam, ab3697) and rabbit anti-matrix GLA protein 
(MGP) (Santa Cruz, sc-66965). Semi-quantitative analyses were performed using the Image-Pro 
software (Media Cybernetics). 
 
2.3. Alcian blue staining. 
Alcian blue staining was performed using the Alcian blue, pH 2.5 kit (VWR), and 
nucleus was counter-stained with Fast Red (VWR). 
 
 2.4. Primary VSMC culture. 
VSMCs were isolated from aortas of six Sm22-/- mice and six Sm22+/+ mice as described 
48. Primary VSMCs were kept in the DMEM medium (Invitrogen) containing 10% FBS 
(Invitrogen) and passed upon confluency at a 1:2 dilution ratio. Primary VSMCs in passage 2 to 
passage 4 were used for experiments. 
 
2.5. Sm22 knockdown in PAC1 cells with siRNA.  
Sm22 knockdown was achieved using Dicer-Substrate siRNA duplexes (IDT, 
MMC.RNAI.N011526.5.1, siA). PAC1 cells 39 (a pulmonary arterial SMC cell line) were seeded 
at 30% confluency 24 hours before transfection. Transfection was performed using 
DharmaFECT3 (Dharmacon) with siRNA duplex or scrambled RNA duplex at 100 nM, and the 
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FBS was diluted to 2% with media 24 hours after transfection for optimal cell density. Cells 
were used for experiments 72 hours after transfection unless otherwise specified. 
 
2.6. RtRT-PCR 
Total RNA from carotid arteries was extracted and purified using RNeasy Fibrous Tissue 
Kit (Qiagen), and total RNA from primary VSMCs or PAC1 cells was extracted and purified 
using RNeasy Kit (Qiagen). The cDNA was synthesized using the Superscript II reverse 
transcriptase (Invitrogen). Real-time PCR was performed using SYBR Green on a StepOnePlus 
system (Applied Biosystems). Gapdh and snRNA U6 were used as internal controls in ΔΔCt 
method. All PCR primers were designed to cover at least 2 exons. 
Gene Forward (5' - 3') Reverse (5' - 3') Size (bp) 
Acan    
Mouse/Rat AGAACCCTCGGGCAGAAGAAAGAT TCTGTAGCCTGTGCTTGTAGGTGT 175 
Acta2    
Mouse/Rat GAGAAGCCCAGCCAGTCG ATCTTTTCCATGTCGTCCCAGTTG 309 
Bmp2    
Mouse TGCGCAGCTTCCATCACGA CTGTGTGGTCCACCGCATCA 329 
Rat TGCTCAGCTTCCATCACGA CTGTGCTGTCCATCGCATCA 329 
Col2a1    
Mouse/Rat TGGAAAGCAAGGTGACCAGGGTAT TTTGGGACCATCAGTACCAGGAGT 163 
Gapdh    
Mouse/Rat TGAATACGGCTACAGCAACAGGGT TTGTGAGGGAGATGCTCAGTGTTG 151 
Myh11    
Mouse/Rat AACGCCCTCAAGAGCAAACTCAGA TCCCGAGCGTCCATTTCTTCTTCA 161 
Myocd    
Mouse/Rat CAGTGAAGCAGCAAATGACTCGG GTCGTTGGCGTAGTGATCGAAGG 230 
Sm22    
Mouse TCCTTCCAGTCCACAAACGACCAA TTTGGACTGCACTTCTCGGCTCAT 92 
Rat TCCTTCCAGCCCACAAACGACCAA CTTGGACTGCACTTCACGGCTCAT 92 
Sox9    
Mouse/Rat GGCGGAGGAAGTCGGTGAAGAA CACGTCGGTTTTGGGAGTGGTG 206 
 
Table 3. List of primer sequence for rtRT-PCR in chondrogenesis. Tm = 60°C for all primers. 
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2.7. Immunofluorescence (IF) analyses.  
PAC1 cells on chamber slides were fixed in methanol for 10 minutes at -20°C and 
blocked with 10% chicken serum for 30 minutes. Then, cells were incubated with primary 
antibodies at 1:100 dilution for 2 hours followed by incubation with Alexa Fluor chicken 
secondary antibodies at 1:200 dilution (Invitrogen) for 1 hour. Slides were mounted with 
Vectashield with DAPI (Vectorlabs) and examined on a Leica DM4000B microscope. 
Quantification was performed using Image-Pro software (Media Cybernetics). Primary 
antibodies were rabbit anti-SM22 IgG (Abcam, ab14106), mouse anti-smooth muscle alpha actin 
(SMA) IgG2a (Santa Cruz, sc-58669) and rabbit anti-SMA antibody (Abcam, ab5694). 
 
2.8. Preparation of cell lysate.  
M-PER Mammalian Protein Extraction Reagent (Pierce) with Halt Protease Inhibitor 
Cocktail (Pierce) was used to prepare whole cell lysates from primary VSMCs and PAC1 cells. 
Cell extracts were stored at -20°C. 
 
2.9. Western blotting (WB). 
Equal amount of whole cell lysates, the nuclear fraction or cytoplasmic fraction from 
primary VSMCs or PAC1 cell samples were loaded on a 4-12% Bis-Tris NuPAGE Mini-gel 
(Invitrogen) for electrophoresis, followed by transfer onto an Immobilon-P membrane 
(Millipore). The membrane was blocked with 5% milk for 30 minutes, followed by primary 
antibody incubation overnight at 4 °C. After incubation with biotinylated secondary antibody for 
30 minutes, the membrane was subjected to enhanced chemiluminescence detection using 
SuperSignal West Pico Chemiluminescent Substrate (Pierce). The primary antibodies were rabbit 
  
32
anti-SM22 IgG (1:1000, Abcam, ab14106), rabbit anti-SMA IgG (1:500, Abcam, ab5694), rabbit 
anti-SOX9 (1:100, Santa Cruz, sc-20095), goat anti-myocardin (1:100, Santa Cruz, sc-21561) 
and rabbit anti-GAPDH (1:2500, Abcam, ab9485). 
 
2.10. Measurement of F/G-actin ratio. 
F/G-actin ratio in PAC1 cells was determined using the G-actin/F-actin in vivo assay kit 
(Cytoskeleton Inc.) according to manufacturer’s protocol. Briefly, PAC1 cells were 
homogenized in cell lysis and F-actin stabilization buffer (50 mmol/L PIPES, 50 mmol/L NaCl, 
5 mmol/L MgCl2, 5 mmol/L EGTA, 5% (v/v) lyceral, 0.1% (v/v) Nonidet P-40, 0.1% (v/v) 
Triton X-100, 0.1% (v/v) Tween 20, 0.1% (v/v) 2-mercaptoethanol and 0.001% (v/v) 
antifoam)and the protease inhibitor cocktail. Centrifugation was performed for 2 hours at 70 000 
g at 37°C to separate the F-actin from G-actin pool and supernatants (G-actin) were collected 
after centrifugation. The pellets (F-actin) were resuspended in ice-cold ddH2O containing 1 
μmol/L cytochalasin D followed by incubation and mixing on ice for 1 h to dissociate F-actin. 
Equal amount of the supernatant (G-actin) and the resuspended pellet (F-actin) were subjected to 
analysis by WB using the rabbit anti-actin antibody in the kit. The quantification was performed 
using the Image-Pro software (Media Cybernetics). 
 
2.11. Statistics.  
Five Sm22-/- mice and five Sm22+/+ littermates were used in histology, IHC and rtRT-
PCR analyses. Primary VSMCs from four Sm22-/- mice and four Sm22+/+ mice were used for 
rtRT-PCR analyses. Three independent experiments were performed in Sm22 knockdown 
research in PAC1 cells. Values are means ± SE. Statistical analyses were performed using 
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SPSS13.0 software (IBM). Student t-test was applied to evaluate differences in all experiments 
and differences were considered significant at p < 0.05.  
 
 
3. Results 
3.1. Enhanced medial chondrogenesis with compromised myogenesis in Sm22-/- mice after 
carotid injury 
Carotid arteries were harvested 2 weeks after carotid artery denudation. IHC analysis 
showed remarkable expression of a chondrocyte marker, type II collagen (Col2a1), in the media 
of Sm22-/- mice (Fig. 8A, B) with morphology of chondrocytic cells (Fig. 9). Alcian blue staining 
revealed marked expression of mucopolysaccharides and glycosaminoglycans in the media of 
Sm22-/- mice (Fig.8Da, Db). A variety of ECM proteins, such as aggrecan (ACAN) and 
osteopontin (SPP1) 70, 71, are required during normal chondrogenesis. IHC analysis indicated that 
expression of both Acan (Fig. 10A) and Spp1 (Fig. 11) in the media was significantly higher in 
Sm22-/- mice compared to their Sm22+/+ littermates. These data support a pro-chondrogenic ECM 
environment in injured arteries of Sm22-/- mice. Furthermore, bone morphogenetic protein 2 
(Bmp2), one of the major cytokines with pivotal roles in every step of chondrogenesis 71, was 
intensely expressed in injured carotid artery media of Sm22-/- mice (Fig. 10B). 
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Figure 8. Enhanced expression of type II collagen in Sm22-/- mice 2 weeks after carotid 
artery denudation. Expression of type II collagen was evaluated by IHC. (A) Injured carotid 
arteries from four Sm22-/- mice and their wild-type littermates at 100X magnification. (B) Both 
injured carotid arteries and non-injured controls at 400X magnification. Representative brown 
signals were indicated by the arrows. (C) Quantification of positive signals from images at 100X 
magnification in the media of carotid arteries from five Sm22-/- and their littermates Sm22+/+ mice. 
(D) Alcian blue staining of carotid arteries at 100X (Da) and at 400X magnification (Db). Blue 
signals, Alcian blue; red signals, nuclear fast red. Bar in (A, Da), 100 µm; bar in (B, Db), 20 µm. 
Dashed lines demarcated the border between media and adventitia. Values are means ± SE. The 
asterisk, *, indicates p < 0.05. 
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Figure 9. Chondrocytic morphology of medial layers in Sm22-/- mice 2 weeks after carotid 
artery denudation. The IHC (type II collagen) image of carotid artery from Sm22-/- mouse of 
pair # 2 in Figure 8 was enlarged to highlight the cell morphology in media layer. Bar, 100 µm. 
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Figure 10. Augmented expression of aggrecan and Bmp2 in Sm22-/- mice 2 weeks after 
carotid artery denudation. (A) IHC analyses of Acan (a) at 100X magnification, (b) at 400X 
magnification and (c) quantification of positive signals from images at 100X magnification in the 
media of carotid arteries from five Sm22-/- and their littermates Sm22+/+ mice. (B) IHC analyses 
of Bmp2 (a) at 100X magnification, (b) at 400X magnification and (c) quantification of positive 
signals from images at 100X magnification in the media of carotid arteries from five Sm22-/- and 
their littermates Sm22+/+ mice. Representative brown signals are indicated by the arrows. Bars in 
(Aa and Ba), 100 µm; Bars in (Ab and Bb), 20 µm. Dashed lines demarcated the border between 
media and adventitia. Values in (Ac and Bc) are means ± SE. The asterisk, *, indicates p < 0.05. 
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Figure 11. Augmented expression of osteopontin in Sm22-/- mice 2 weeks after carotid 
artery denudation. (A) IHC analyses of osteopontin (Spp1) (a) at 100X magnification, (b) at 
400X magnification and (c) quantification of positive signals from images at 100X magnification 
in the media of carotid arteries from five Sm22-/- and their littermates Sm22+/+ mice. 
Representative brown signals are indicated by the arrows. Bar in (Aa), 100 µm; Bar in (Ab), 20 
µm. Dashed lines demarcated the border between media and adventitia. Values in (Ac) are 
means ± SE. The asterisk, *, indicates p < 0.05.  
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In order to explore the transcriptional basis underlying the ectopic chondrogenesis, we 
examined expression of a master transcription factor regulating chondrogenesis, SOX9 71, 72. IHC 
results showed marked Sox9 expression in the media of the injured carotid arteries from Sm22-/- 
mice in contrast to the scant Sox9 induction from Sm22+/+ littermates (Fig. 12A). We also 
examined the mRNA level of myocardin in the media of the injured carotid arteries. The 
expression of myocardin decreased significantly in injured carotid arteries of Sm22-/- mice 
compared to that of their Sm22+/+ littermates (60% vs. 20%, Fig.12B), suggesting a lower pro-
myogenic tendency in the VSMCs of Sm22-/- mice after injury. The expression of smooth muscle 
myosin heavy chain (Myh11) was reduced, although this reduction was not statistically 
significant (Fig. 12B).  However, the expression of smooth muscle alpha actin (Acta2) mRNA 
was not affected much (Fig. 12B); this could be due to the fact that Acta2 is also expressed in 
adventitial cells after injury in addition to medial VSMCs. This speculation is supported by IHC 
analysis of Acta2 (Fig. 13). 
 
On the other hand, we did not find calcium deposition in carotid arteries from either 
Sm22-/- mice or their Sm22+/+ littermates based on the negative results of Alizarin Red staining. 
Meanwhile, we analyzed expression of osteocalcin (Bglap), alkaline phosphatase (Alp) and 
Runx2 using IHC and found little difference between these two groups. These results indicated 
the lack of medial calcification at this time point. 
 
These in vivo findings illustrate a transcriptional shift from pro-myogenesis to pro-
chondrogenesis in the arteries of Sm22-/- mice upon stress; this suggests that loss of Sm22 in 
VSMCs might promote the ectopic medial chondrogenesis via transcriptional switch.  
  
40
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Augmented expression of Sox9 in Sm22-/- mice 2 weeks after carotid artery 
denudation. (A) IHC analyses of Sox9 (a) at 100X magnification, (b) at 400X magnification 
and (c) quantification of positive signals from images at 100X magnification in the media of 
carotids from five Sm22-/- and their littermates Sm22+/+ mice. Representative brown signals were 
indicated by the arrows. Bar in (Aa, 100 µm; Bar in (Ab), 20 µm.  (B) Relative mRNA level of 
Myocd, Acta2 and Myh11 in injured carotids was evaluated using rtRT-PCR. Dashed lines 
demarcated the border between media and adventitia. Values in (Ac and B) are means ± SE. The 
asterisk, *, indicates p < 0.05 versus Sm22+/+ mice.  
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Figure 13. Lower expression of Acta2 in Sm22-/- mice 2 weeks after carotid artery 
denudation. (A) IHC analyses of Acta2 (a) at 100X magnification, (b) at 400X magnification 
and (c) quantification of positive signals from images at 100X magnification in the media of 
carotid arteries from five Sm22-/- and their littermates Sm22+/+ mice. Representative brown 
signals are indicated by the arrows. Bar in (Aa), 100 µm; Bar in (Ab), 20 µm. Dashed lines 
demarcated the border between media and adventitia. Values in (Ac) are means ± SE. 
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3.2. A transcriptional shift from myogenic to chondrogenic pattern in primary Sm22-/- 
VSMCs and after Sm22 knockdown in a VSMC line 
To explore the transcriptional changes after Sm22 disruption in VSMCs, we investigated 
expression of several marker genes in primary VSMCs from Sm22-/- mice and their Sm22+/+ 
littermates and in PAC1 cells after Sm22 knockdown. The mRNA levels of Myocd, Smtn, Acta2 
and Myh11 in Sm22-/- VSMCs were lower than those in Sm22+/+ VSMCs (Fig. 14A), while the 
mRNA levels of Sox9, Bmp2 and Col2a1 were higher in Sm22-/- VSMCs (Fig. 14A). The 
expressions of Act2 and Sox9 proteins were also decreased and increased respectively in Sm22-/- 
VSMCs by WB (Fig. 14A, inserted panel). We tried to detect Myocd protein in primary VSMCs 
using WB but failed after several attempts. In PAC1 cells, the decrease of Myocd, Smtn, Acta2 
and Myh11 mRNA correlated with the increased Sm22 knockdown efficiency over time after 
siRNA treatment (Fig. 14B). In contrast, the expression of Sox9 mRNA gradually increased (Fig. 
14B), although the mRNA levels of Col2a1 and Acan were not upregulated in the VSMC culture 
conditions (data not shown). Accordingly, WB revealed decreased expression of Myocd and 
Acta2 and increased expression of Sox9 in PAC1 three days after Sm22 siRNA treatment (Fig. 
14B, inserted panel). These data suggest a switch from myogenesis to chondrogenesis in VSMCs 
after Sm22 disruption: this led us to ask how disruption of an actin cytoskeletal protein alters 
VSMC fate. 
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Figure 14. Chondrogenic switch of VSMCs in primary Sm22-/- VSMCs and in PAC1 cells 
after Sm22 knockdown. (A) In primary Sm22-/- and Sm22+/+ VSMCs, relative mRNA 
expression of Myocd, Smtn, Acta2, Myh11, Sox9, Bmp2 and Col2a1 was examined using rtRT-
PCR and WB (inserted panel). Values are means ± SE from primary VSMCs of four pairs of 
mice. (B) In PAC1 cells, Sm22 knockdown efficiency and the expression of Myocd, Smtn, Acta2, 
Myh11 and Sox9 were determined by rtRT-PCR 1 day, 2 days and 3 days after transfection, and 
by WB (inserted panel) 3 days after transfection. Values are means ± SE from three independent 
experiments. The asterisk, *, indicates p < 0.05. Abbreviations: scr, scrambled siRNA; si, Sm22 
siRNA; d1/2/3, 1/2/3 days after transfection into PAC1 cells. 
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3.3 Altered morphology in primary Sm22-/- VSMCs and in PAC1 cells after Sm22 
knockdown  
Disruption of actin cytoskeleton and increased actin dynamics in mesenchymal cells are 
known to lead to chondrogenesis 73. Since SM22 is an actin binding protein, we propose that 
disruption of Sm22 might affect actin cytoskeleton and actin dynamic. After passage 2, the 
primary Sm22-/- VSMCs displayed remarkable morphological changes, in which they lost their 
spindle-shaped appearance and became spherical (Fig. 5A). We observed a similar 
morphological change after Sm22 knockdown in PAC1 cells (Fig. 5B). We then used IF to 
visualize the actin cytoskeleton in PAC1 cells. Abundant actin stress fibers co-localized with 
Sm22 in control PAC1 cells (Fig. 5C, upper panel). However, there was scant actin stress fiber 
formation after Sm22 knockdown (Fig. 5C, lower panel). We further evaluated actin dynamics by 
G/F-actin ratio and found significant increase (ca. 3-fold) of G/F-actin ratio after Sm22 
knockdown (Fig. 5D). These alterations in cell morphology and actin dynamics could be 
indications of chondrogenic shift of VSMCs. 
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Figure 15. Altered morphology in primary Sm22-/- VSMCs and in PAC1 cells after Sm22 
knockdown. (A) Two views of phase contrast images from primary Sm22-/- and Sm22+/+ VSMCs 
at passage 4. Bar, 50 µm. (B) The phase contrast images from PAC1 cells in the absence or 
presence of Sm22 siRNA. Bar, 20 µm. (C) Expression of Sm22 and Sma was investigated using 
IF. Bars, 20 µm. (D) Actin dynamics was determined by G/F-actin ratio in PAC1 cells without or 
with Sm22 siRNA. Values are means ± SE from three independent experiments. The asterisk, *, 
indicates p < 0.05.  
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4. Discussion 
The results presented above show that disruption of Sm22 in VSMC promoted conversion 
of medial VSMC into chondrogenic cells in response to artery injury. This notion is further 
supported by in vitro experiments using primary VSMCs from Sm22-/- mice and PAC1 after 
Sm22 knockdown. 
 
4.1. Arterial chondrogenesis and limitations of current in vivo model 
Although arterial chondrogenesis occurs in the diseased vessel wall, it may share certain 
common cellular and molecular events and signaling pathways with chondrogenesis during 
normal development 7, 8, 71. First, a variety of ECM proteins are expressed distinctly in different 
stages of chondrogenesis. Proliferation and differentiation of chondroprogenitors are maintained 
by the ECM structure composed of type II collagen, a hallmark of chondrogenesis, and aggrecan, 
a major chondrogenic proteoglycan 71. Chondrocyte terminal differentiation hypotrophy and 
calcification correlate with the expression of such ECM proteins as osteopontin and osteocalcin 
52, 68, 70, 71.  In the media of injured carotid arteries of Sm22-/- mice, we observed high expression 
of ECM proteins including type II collagen, aggrecan and osteopontin. This suggests the 
existence of a pro-chondrogenic ECM environment in the injured carotid arteries of Sm22-/- mice. 
Second, BMP2 is a cytokine with multifaceted functions required for almost every stage of 
chondrogenesis 71: we did find that Bmp2 is highly induced in the media of injured carotid 
arteries of Sm22-/- mice. Finally, the key transcriptional regulator of chondrogenesis, Sox9 71, 72, 
is also highly expressed, reflecting the activation of pro-chondrogenic transcription in the media 
of the injured Sm22-/-carotid arteries.  
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Our in vivo results suggest that downregulation of Sm22 may expedite arterial 
chondrogenesis. This may, at least in part, explain why downregulation of VSMC markers 
including SM22 is found in arterial calcification 8, 34, 52, 68. Nevertheless, it is still unclear whether 
this pro-chondrogenic property of the injured arteries in Sm22-/- mice derives from the VSMCs or 
from other types of cells in the artery wall. Besides, we only observed marginal neointima 
formation in injured carotid arteries: this might be due to the C57BL6 mice having mixed genetic 
background that may be resistant to injury-induced neointima formation 66.  It is also noteworthy 
that we did not gain evidence of arterial calcification. There are at least two possibilities: either 
that the terminal stage of endochondral calcification requires an extended process beyond the 2-
week period in current injury model, or that arterial chondrogenesis could exist as an 
independent state free of calcification. To answer this question, prolonged post-injury time in the 
carotid artery denudation model or other injury models such as carotid ligation could be used in 
further studies.  
 
4.2. Chondrogenic phenotypic modulation of VSMC and limitations of the in vitro model 
VSMCs are highly plastic and undergo multifaceted phenotypic changes during the 
pathogenesis of arterial diseases. Under physiological condition, VSMCs express an array of 
VSMC contractile and cytoskeleton proteins. In response to injury, VSMCs lose their contractile 
phenotype, increase actin dynamics and acquire the phenotypes of other cell types including 
chondrocytic cells 3, 17, 52, 69. The cell fate is determined by the interplay of key transcription 
factors and signaling pathways, which downregulates VSMC markers and upregulates markers 
of other lineages.       
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It is known that VSMCs derive from mesenchymal cells and that disruption of actin 
cytoskeleton with increased actin dynamics in mesenchymal cells leads to chondrogenesis 73. 
Therefore, disrupted actin stress fibers and loss of VSMC morphology may be indicative of 
chondrogenic conversion. We observed similar morphologic alteration from the spindle-shaped 
appearance typical of differentiated VSMCs to the spherical appearance of chondrocytes in 
primary Sm22-/- VSMCs and PAC1 cells after Sm22 knockdown. Furthermore, knockdown of 
Sm22 resulted in compromised actin stress fiber formation and increased actin dynamics: this 
agrees with the findings in a VSMC primary culture system treated with antisense Sm22 74.  
 
Structural changes in cells are often associated with transcriptional reprogramming, and 
morphologic changes in early endochondral bone formation correlate with the activation of 
chondrogenic transcription 71, 75. Among others, SOX9 is one key transcription factor that 
controls the expression of chondrogenic ECM proteins including type II collagen and aggrecan 71, 
72. On the other hand, myocardin is a master transcription factor of VSMCs since it is necessary 
and sufficient to transactivate SMC markers including SMA and SM22 76, 77. In our in vitro 
investigation, along with the cell morphologic transformation after Sm22 knockdown, the 
suppressed myocardin expression and augmented expression of Sox9 was consistent with such a 
transcriptional shift favoring chondrogenesis over myogenesis. 
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PART III 
Reactive Oxygen Species (ROS) Mediated NF-κB Activation  
After Sm22 disruption Couples Pro-inflammatory  
And Chondrogenic Phenotypes Of VSMCs 
 
1. Introduction 
A body of reports linked inflammation with arterial osteochondrogenesis in a variety of 
arterial diseases 78, so it is interesting that we observed prominent inflammation and medial 
chondrogenesis simultaneously in the Sm22-/- mice. Meanwhile, results from experiments in 
primary Sm22-/- VSMCs and PAC1 cells support the coupling of both pro-inflammatory 
phenotype and chondrogenic phenotype of VSMCs after Sm22 disruption. Nevertheless, it is 
elusive whether these two phenotypes of VSMCs share common molecular signaling pathways 
and transcriptional regulation network. Among other signaling pathways of inflammation, NF-
κB pathway is relatively well characterized. However, NF-κB pathway is conventionally deemed 
as anti-chondrogenic due to the fact that Sox9, the key transcription factor during chondrogenesis, 
is downregulated in response to inflammatory stimuli 79-81. This concept has been challenged by 
several recent studies demonstrating that NF-κB pathway participates in early chondrogenesis 82-
84. Therefore, we hypothesized that NF-κB activation may underlie the coupling of pro-
inflammatory and chondrogenic phenotypes of VSMCs after Sm22 disruption. 
 
2. Materials and Methods 
2.1. Immunohistochemical (IHC) analyses. 
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Six slides, in the order of one every 15 consecutive slides, from each mouse were subject 
to H&E staining to screen sections with most prominent inflammatory responses. IHC was 
performed on the properly selected consecutive frozen slides using VECTASTAIN Elite ABC 
Kit (Vectorlabs). Briefly, air-dried slides were fixed in methanol containing 0.3% H2O2 for 10 
minutes and serum blocked for 20 minutes. The following incubation steps of primary antibody, 
secondary antibody, ABC reagent and DAB substrate were performed according to the 
manufacturer’s protocol. The slides were counterstained with hematoxylin. The primary 
antibodies (1:50 dilution) were against RELA (Santa Cruz, sc-109) and NFKB2 (Abcam 
ab31409).  
 
2.2. Morphometric analysis 
For each antibody, both 100X and 400X images were taken using a Leica DM4000B 
microscope (Leica). Images of adventitia and media were separated using Photoshop 7.0 
software. Semi-quantitative analyses of positive signals in adventitia and media were performed 
on all 100X images using color segmentation and integrative optical density function in the 
Image-Pro software (Media Cybernetics).  
 
2.3. Sm22 knockdown in PAC1 cells with siRNA.  
Sm22 knockdown was achieved using Dicer-Substrate siRNA duplexes (IDT, 
MMC.RNAI.N011526.5.1, siA). PAC1 cells 39 (a pulmonary arterial SMC cell line) were seeded 
at 30% confluency 24 hours before transfection. Transfection was performed using 
DharmaFECT3 (Dharmacon) with siRNA duplex or scrambled RNA duplex at 100 nM, and the 
FBS was diluted to 2% with media 24 hours after transfection for optimal cell density. In parallel 
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experiments, the following small molecules were added respectively 24 hours after transfection: 
NF-κB inhibitors, Bay-11-7082 (10 μM) and IMD-0354 (200 nM); ROS scavengers, Tiron (5 
mM), Tempol (1 mM) and NAC (5 mM); NADPH oxidase and mitochondria complex I inhibitor, 
DPI (5 μM). Cells were used for experiments 72 hours after transfection unless otherwise 
specified. Two other siRNA duplexes (IDT, MMC.RNAI.N011526.5.2, designated as siC and 
IDT, MMC.RNAI.N011526.5.3, designated as siB) were also used independently at 200 nM 
concentration to rule out off-target effects of the siRNAs. 
 
2.4. Immunofluorescence (IF).  
PAC1 cells on chamber slides were fixed in methanol for 10 minutes at -20°C and 
blocked with 10% chicken serum for 30 minutes. Then, cells were incubated with primary 
antibodies at 1:100 dilution for 2 hours followed by incubation with Alexa Fluor chicken 
secondary antibodies at 1:200 dilution (Invitrogen) for 1 hour. Slides were mounted with 
Vectashield with DAPI (Vectorlabs) and examined on a Leica DM4000B microscope (Leica). 
Quantification was performed using Image-Pro software (Media Cybernetics). Primary 
antibodies were against SOD2 (Abcam, ab13533), p47phox (Santa Cruz, sc-14015), and α-
tubulin (Cellsignaling, 2125S). 
 
2.5. Preparation of cell lysate and nuclear extracts.  
M-PER Mammalian Protein Extraction Reagent (Pierce) with Halt Protease Inhibitor 
Cocktail (Pierce) was used to prepare whole cell lysates from primary VSMCs and PAC1 cells, 
and NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce) with Halt Protease Inhibitor 
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Cocktail (Pierce) were used to prepare the nuclear fraction and cytoplasmic fraction from 
primary VSMCs and PAC1 cells. Nuclear extracts were stored at -70°C. 
 
2.6. Western blotting.  
Equal amount of whole cell lysates, the nuclear fraction or cytoplasmic fraction from 
primary VSMCs or PAC1 cell samples were loaded on a 4-12% Bis-Tris NuPAGE Mini-gel 
(Invitrogen) for electrophoresis, followed by transfer onto an Immobilon-P membrane 
(Millipore). The membrane was blocked with 5% milk for 30 minutes, followed by primary 
antibody incubation overnight at 4°C. After incubation with biotinlyated secondary antibody for 
30 minutes, the membrane was subject to enhanced chemiluminescence detection using 
SuperSignal West Pico Chemiluminescent Substrate (Pierce). The primary antibodies were 
against RELA (1:1000, Santa Cruz, sc-109X), NFKB2 (1:1000, Abcam ab31409), IKB (1:1000, 
Abcam, ab32518), SOD2 (Abcam, ab13533) and GAPDH (1:2500, Abcam, ab9485). 
 
2.7. In vitro NF-κB binding activity.  
Equal amount of nuclear extracts (5 μg) from PAC1 samples were incubated with an 
IRDye 700 labeled NF-κB probe (LI_COR) in the binding buffer for 30 minutes. The binding 
mixtures were loaded on a 6% DNA retarding gel (Invitrogen) for electrophoresis. The gel was 
then examined on an Odyssey Infrared Imaging System (LI-COR) for visualization of NF-κB 
bound probes. 
 
2.8. ROS detection.  
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ROS in live primary VSMCs or PAC1 cells was detected using dihydroethidium (DHE, 
Invitrogen) for superoxide and the Image-iT™ LIVE Green ROS detection kit (Invitrogen) for 
peroxide. Cells on chamber slides were incubated at 37°C with 10 μM of DHE for 10 minutes or 
25 μM of carboxy-H2DCFDA for 30 minutes and the fluorescent signals were examined 
immediately on a Leica DM4000B microscope (Leica) and the fluorescence signals were 
captured at 2-second exposure time for each 400X field by the Leica DFC350 digital 
monochrome camera. Semi-quantitative analyses were performed on 30 images (15 - 30 
cells/image) of each group from the same batch of experiments using integrative optical density 
function in the Image-Pro software (Media Cybernetics). 
 
2.9. Statistics.  
Five Sm22-/- mice and five Sm22+/+ littermates were used in histology and IHC analyses. 
Three independent experiments were performed to knockdown Sm22 in PAC1 cells. Values are 
means ± SE. Statistical analyses were performed using SPSS13.0 software (IBM). Student t-test 
was applied to evaluate differences in all experiments and differences were considered 
significant at p < 0.05.  
 
3. Results 
3.1. NF-κB pathways were highly activated in injured carotid arteries of Sm22-/- mice 
The activation of multiple pro-inflammatory genes in injured carotid arteries of Sm22-/- 
mice suggested their transcriptional co-regulation. The NF-κB pathways are key pro-
inflammation pathways, and the aforementioned pro-inflammatory molecules are targets of 
activated NF-κB. Thus, we examined whether NF-κB activation was higher in injured carotid 
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arteries of Sm22-/- mice than in those of their Sm22+/+ littermates. The activation of NF-κB 
pathways was shown by the ratio of number of RELA or NFKB2 positive nuclei to the number 
of all nuclei in the media from five Sm22-/- mice and Sm22+/+ littermates (Fig. 16A, B, the bottom 
panel). As a canonical NF-κB pathway activation marker, the nuclear RELA (also known as p65) 
appeared to be higher (about 1.5 times) in Sm22-/- mice (Fig. 16A, bottom panel). However, the 
nuclear NFKB2 (also known as p52), a non-canonical NF-κB pathway activation marker, was 
significantly higher (more than 2 times) in Sm22-/- mice (Fig. 16B, bottom panel). Consistent 
with this observation, we detected more nuclear NFKB2 protein in primary Sm22-/- VSMCs (Fig. 
17) by WB using nuclear extracts, while we failed to detect nuclear RELA in either Sm22+/+  or 
Sm22-/- primary VSMCs (Fig. 17). The difference in nucleus distribution pattern between RELA 
and NFKB2 suggested that the non-canonical NF-κB pathway may be involved in transactivating 
NF-κB target genes under this condition.  
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Part IV 
Identifying Col1a2 as an SRF target gene 
 
Figure 16. Activation of NF-κB pathway in Sm22-/- mice 2 weeks after carotid artery 
denudation. Activation of both canonical NF-κB RELA (A), and non-canonical NF-κB NFKB2 
(B) was evaluated by IHC. Top panels, 100X; middle panels, 400X. In the middle panel 
representative positive signals (brown) are indicated by arrows, and nuclear NFKB2 is indicated 
by arrow heads. Bottom panels: the ratio of signal positive nuclei versus all nuclei in the same 
area of the media of carotid arteries from five Sm22-/- and their littermates Sm22+/+ mice as 
quantified using Image-Pro software. Values are means ± SE. The asterisk, *, indicates p < 0.05. 
Bars: top panels, 100 µm; middle panels, 20 µm. 
 
 
  
59
 
 
 
 
Figure 17. Nuclear expression of NF-κB subunits in primary Sm22-/- VSMCs. Nuclear 
lysates from Sm22-/- and Sm22+/+ VSMCs were investigated using WB for RELA (upper panel) 
and NFKB2 expression (lower panel). 
 
3.2. NF-κB pathways were activated after Sm22 knockdown and contributed to 
upregulation of inflammatory gene expression 
To test whether NF-κB was also activated after Sm22 knockdown, we performed WB 
using cytoplasmic and nuclear fractions from PAC1 cells. After Sm22 knockdown, the 
cytoplasmic IκB level decreased, while the nuclear RELA level increased drastically; this effect 
was diminished by Bay-11-7082 (a NF-κB pathway inhibitor) (Fig. 18A). Since degradation of 
cytoplasmic IκB and nuclear translocalization of RELA reflect activation of the canonical NF-κB 
pathway85, we concluded that Sm22 knockdown in PAC1 cells activated the canonical NF-κB 
pathway. Sm22 knockdown increased NFKB2 protein level (Fig. 18B); Bay-11-7082 inhibited 
the processing of p100, the NFKB2 precursor, into NFKB2 and prevented NFKB2 from nuclear 
translocation upon Sm22 knockdown (Fig. 18B). These findings indicated that Sm22 disruption 
activated NF-κB pathways, consistent with the above in vivo observation. We further tested 
alteration of nuclear NF-κB binding activity in PAC1 cells after Sm22 knockdown using a 
consensus NF-κB probe. The NF-κB binding activity was increased after Sm22 knockdown (Fig. 
18C), and Bay-11-7082 reduced this increase (Fig. 18C). We then investigated whether NF-κB 
activation participates in the induction of the aforementioned pro-inflammatory genes. As shown 
in Fig. 6, NF-κB inhibitor Bay-11-7082 significantly reduced the transcriptional increase of these 
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five genes (Fig. 19) and of Vcam1 protein in PAC1 cells after Sm22 knockdown (Fig. 19 inset). 
A similar effect was also observed using another NF-κB pathway (IKKbeta) inhibitor, IMD-0354 
(Fig. 20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Sm22 knockdown activated NF-κB pathways. Cytoplasmic and nuclear lysates 
were isolated from PAC1 cells transfected with scrambled RNA (scr) or Sm22 siRNA (si). 
Activation of both canonical NF-κB pathway (A) and non-canonical NF-κB pathway (B) was 
investigated by WB using antibodies against RELA, IKB and NFKB2 as indicated. P100 is the 
precursor of NFKB2. NF-κB binding activitiy of nuclear extracts was investigated using a NF-
κB consensus binding site as the probe (C), showing increased NF-κB binding activities after 
Sm22 knockdown. Data are from three independent experiments. scr, scrambled siRNA; si, Sm22 
siRNA, NS: nonspecific. 
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Figure 19. NF-κB inhibitor Bay-11-7082 blocked induction of pro-inflammatory genes after 
Sm22 knockdown. PAC1 cells transfected with scrambled RNA (scr) or Sm22 siRNA (si) in the 
absence or presence of Bay-11-7082 (Bay), an NF-κB pathway inhibitor. Effect of Bay-11-7082 
on induction of inflammatory genes was investigated using rtRT-PCR and WB (inserted panel). 
Values are means ± SE. The asterisk, *, indicates p < 0.05. Data are from three independent 
experiments. 
 
 
 
 
 
 
 
  
62
 
 
 
 
 
 
 
 
 
 
 
Figure 20. NF-κB inhibitor IMD-0354 blocked induction of pro-inflammatory genes after 
Sm22 knockdown. PAC1 cells transfected with scrambled RNA (scr) or Sm22 siRNA (si) in the 
absence or presence of IMD-0354 (IMD), an NF-κB pathway inhibitor. Effect of IMD-0354 on 
induction of inflammatory genes was investigated using rtRT-PCR and WB (inserted panel). 
Values are means ± SE. The asterisk, *, indicates p < 0.05. Data are from three independent 
experiments.  
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3.3. NF-κB pathways activation after Sm22 knockdown contributed to induction of Sox9  
NF-κB signaling pathway was recently shown to participate in Sox9 expression and 
chondrogenesis 82, 84. We showed that NF-κB pathway is activated after Sm22 knockdown in 
PAC1 cells. Thus, we tested whether NF-κB activation contributed to the up-regulation of Sox9 
after Sm22 knockdown. After inhibition of the NF-κB pathway during Sm22 knockdown in 
PAC1 cells using NF-κB inhibitors, Bay-11-7082 or IMD-0354, transcriptional activation of 
Sox9 was significantly reduced (Fig. 21). Consistently, WB results showed that increased Sox9 
protein was suppressed by Bay-11-7082 (Fig. 21, inserted panel). These results suggest that NF-
κB pathway activation mediates the transcriptional activation of Sox9 after Sm22 knockdown. 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. NF-κB inhibitors blocked induction of Sox9 after Sm22 knockdown. PAC1 cells 
transfected with scrambled RNA (scr) or Sm22 siRNA (si) in the absence or presence of either of 
the two NF-κB pathway inhibitors, Bay-11-7082 (Bay) or IMD-0354 (IMD). Expression of Sox9 
was evaluated using rtRT-PCR and WB (inserted panel). Values are means ± SE from three 
independent experiments. The asterisk, *, indicates p < 0.05.  
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These data demonstrate that NF-κB pathway was activated upon Sm22 disruption in 
PAC1 cells and promoted the transactivation of both pro-inflammatory genes and the key 
chondrogenic transcription factor Sox9. However, the issue of how NF-κB activation occurs after 
disruption of an actin cytoskeleton protein remains to be addressed. NF-κB is a redox-sensitive 
transcription factor 86, and expression of Sox9 can be activated by ROS dependent transcription 
factors during developmental chondrogenesis 75. Thus we hypothesized that NF-κB activation 
after Sm22 knockdown might be initiated by ROS increase after Sm22 knockdown in PAC1 cells. 
 
3.4. Boosted ROS production after Sm22 knockdown in PAC1 cells contributed to NF-κB 
activation and induction of pro-inflammatory genes 
We investigated ROS production based on fluorescence microscopy using DHE for 
superoxide and DCFDA for peroxide. Levels of both superoxide (Fig. 22A, E) and peroxide (Fig. 
22B, E) were about 30% higher in Sm22-/- primary VSMCs, and 50% higher after Sm22 
knockdown in PAC1 cells (Fig. 22C, D, F). To test whether the boosted ROS level contributed to 
NF-κB activation after Sm22 knockdown, we used Tiron (a ROS scavenger) or Tempol (a 
superoxide scavenger), to neutralize the ROS (Fig. 22C, D, F). Tiron decreased the expression of 
both nuclear RELA (Fig. 23A) and nuclear NFKB2 (Fig. 23B), indicating inhibition of NF-κB 
pathways. These data indicate that ROS might act upstream of the NF-κB activation. 
Interestingly, it appears that superoxide rather than peroxide mediated most of these effects since 
Tempol lowered superoxide without significantly decreasing the elevated peroxide level and 
Tiron also reduced the production of superoxide more than that of peroxide (Fig. 22F). 
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Figure 22. Elevated ROS production after Sm22 disruption.  
(A-B) Primary VSMCs were subjected to fluorescence microscopy after DHE staining for 
superoxide detection (A) or DCFDA for peroxide (B). (C-D) PAC1 cells with Sm22 siRNA 
transfection were also subjected to fluorescence microscopy after DHE (C) or DCFDA (D) 
staining with or without Tiron or Tempol. (E) Quantification of images in (A) and (B). (F) 
Quantification of images in (C) and (D). Abbreviations: scr, scrambled RNA; si, Sm22 siRNA; 
Ti, Tiron; Te, Tempol. Data were from three independent experiments. 
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Figure 23. Elevated ROS production after Sm22 disruption contributed to NF-κB 
activation. In PAC1 cells, activation of both canonical NF-κB pathway (A) and non-canonical 
NF-κB pathway (B) was investigated respectively by WB using antibodies against RELA, IKB 
and NFKB2 as indicated. P100 is the precursor of NFKB2. Dashed line, images of non-adjacent 
lanes on the same gel. Abbreviations: scr, scrambled RNA; si, Sm22 siRNA; Ti, Tiron; Te, 
Tempol. 
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3.5. Boosted ROS production after Sm22 knockdown induced pro-inflammatory genes 
To test if the elevated ROS contributes to induction of pro-inflammatory genes after 
Sm22 knockdown, we neutralized ROS with Tiron (Fig. 24A) or Tempol (Fig. 24B) or N-acetyl-
cysteine (NAC, a ROS scavenger) (Fig. 24C) respectively. Any of the three reagents blocked the 
upregulation of NF-κB inducible pro-inflammatory genes after Sm22 knockdown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Elevated ROS production after 
Sm22 disruption induced activation of 
pro-inflammatory genes. PAC1 cells 
transfected with scrambled RNA (scr) or 
Sm22 siRNA (si) in the absence or presence 
of Tiron (A) or Tempol (B) or NAC (C). 
The blocking effect on pro-inflammatory 
gene induction after Sm22 knockdown using 
rtRT-PCR and WB (inserted panel in A). 
Values were means ± SE. The asterisk, *, 
indicates p < 0.05. Abbreviations: scr, 
scrambled RNA; si, Sm22 siRNA; Ti, Tiron; 
Te, Tempol. Data were from three 
independent experiments. 
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3.6. Boosted ROS production after Sm22 knockdown induced Sox9 expression 
To inspect if the elevated ROS contributes to Sox9 induction after Sm22 knockdown, we 
abolished ROS increase using Tiron (Fig. 25, si+Ti group vs. si group). For easy comparison, we 
show in the figure boosted ROS production (DHE and DCFDA) after Sm22 knockdown (Fig. 25, 
si group vs. scr group). After interference by Tiron upon Sm22 knockdown, transcriptional 
activation of Sox9 was significantly suppressed (Fig. 25, Sox9 columns, si+Ti group vs. si group). 
Accordingly, increased expression of Sox9 protein was also suppressed by Tiron as shown by 
WB analyses (Fig. 25, inserted panel). 
 
 
 
 
 
 
 
 
 
 
Figure 25. Elevated ROS production induced Sox9 expression after Sm22 knockdown. 
PAC1 cells transfected with scrambled RNA (scr) or Sm22 siRNA (si) in the absence or presence 
of Tiron. ROS levels were evaluated by DHE and DCFDA. Sox9 expression was investigated 
using rtRT-PCR (Sox9 bars) and WB (inserted panel). Values are means ± SE from three 
independent experiments. The asterisk, *, indicates p < 0.05. 
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3.7. ROS produced by both mitochondria and NADPH oxidase might be facilitated by 
disorganized cytoskeleton in the absence of Sm22 
In order to locate the sources of the elevated ROS after Sm22 disruption, we scanned 
mRNA expression of known ROS production related genes including SOD system, NADPH 
oxidase system, dual oxidase, catalase and glutathione peroxidase 87. Sod2 mRNA in PAC1 after 
Sm22 knockdown increased about 2.5 times by rtRT-PCR (Fig. 26A); the Sod2 increase was 
confirmed by WB (Fig. 26B) and IF (Fig. 26C). In accordance, Sod2 mRNA induction by injury 
was also higher in Sm22-/- mice compared to their Sm22+/+ littermates (Fig. 26A); however, this 
difference was not statistically significant between primary VSMCs from Sm22+/+ and Sm22-/- 
mice (Fig. 26A). Since Sod2 is a known NF-κB target 88, NF-κB activation may plausibly induce 
Sod2 expression. Indeed, the upregulation of Sod2 after Sm22 knockdown was repressed by Bay-
11-7082 (a NF-κB pathway inhibitor) (Fig. 26B). It is known that SOD2 is a mitochondrial 
matrix protein and scavenges mitochondrial superoxide, the increase of Sod2 suggested boosted 
mitochondrial superoxide production as a feedback. Further observation on mitochondria 
morphology and distribution revealed mitochondria aggregation and fusion into 
megamitochondria (Fig. 27) which is associated with ROS production 89. 
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Figure 26. Induction of Sod2 after Sm22 disruption. (A) Expression of Sod2 mRNA in PAC1 
cells transfected with scrambled RNA (scr) or Sm22 siRNA (si), primary VSMCs (P) and injured 
mouse carotid arteries (M) was investigated using rtRT-PCR. Values are means ± SE. The 
asterisk, *, indicates p < 0.05. (B) Sm22 knockdown induced Sod2 protein expression, and this 
induction was repressed by Bay-11-7082 (Bay, a NF-κB inhibitor) as shown in WB. (C) 
Induction of Sod2 after Sm22 knockdown was shown in IF. 
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Figure 27. Altered mitochondria organization after Sm22 disruption. Mitotracker Red was 
used to visualize mitochondria. Mitochondria aggregation and megamitochondria after Sm22 
knockdown in PAC1 cells are indicated by arrows and arrow heads respectively. Abbreviations: 
scr, scrambled RNA; si, Sm22 siRNA. 
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Moreover, we observed that Sm22 knockdown induced cell periphery translocation of 
p47phox (Fig. 28A), an indication of NADPH oxidase activation 90. Diphenyleneiodonium (DPI), 
an inhibitor of both NADPH oxidase and mitochondrial complex I, significantly blocked the 
upregulation of pro-inflammatory genes and Sox9 after Sm22 knockdown (Fig. 28B). Therefore, 
mitochondria and NADPH oxidase may both contribute to the elevated ROS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28. Activation of NADPH 
oxidase after Sm22 disruption. (A) 
Cell peripheral assembly of p47phox 
after Sm22 knockdown was 
investigated with a p47phox 
antibody and indicated by arrows. 
(B) Suppression of induction of pro-
inflammatory genes and Sox9 by DPI 
(an NADPH oxidase inhibitor) was 
evaluated using rtRT-PCR. Values 
are means ± SE. The asterisk,*, 
indicates p < 0.05. Abbreviations: 
scr, scrambled RNA; si, Sm22 
siRNA; 
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Since SM22 is an actin associated protein and NADPH oxidase activation might be 
affected by change in actin cytoskeleton organization 90, we examined the actin cytoskeleton and 
observed significantly less actin stress fiber in PAC1 cells after Sm22 knockdown (Fig. 15C). 
Microtubules and actin cytoskeleton cooperate functionally during a variety of cellular processes 
and regulate mitochondria distribution91; therefore, we examined whether Sm22 disruption affect 
the microtubule cytoskeleton. We found that microtubules were unevenly distributed in the Sm22 
knockdown cells and displayed local aggregation (Fig. 29). These results suggest that 
cytoskeleton remodeling induced by disruption of Sm22 in VSMCs might activate multiple ROS 
production machineries. 
 
 
 
 
 
 
 
Figure 29. Altered microtubule organization after Sm22 disruption. Microtubule structure 
was investigated using IF with a tubulin antibody (TUB), and the aggregation of tubulin after 
Sm22 knockdown in PAC1 cells is indicated by arrows. Abbreviations: scr, scrambled RNA; si, 
Sm22 siRNA. 
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4. Discussion 
4.1. ROS mediated NF-κB activation as a shared molecular switch between inflammation 
and chondrogenesis after Sm22 disruption 
NF-κB was initially identified in leukocytes. Activation of NF-κB pathways is well 
documented during arterial inflammation and just recently discovered during chondrogenesis 82-
84. All aforementioned pro-inflammatory genes 42-44 and Sox9 84 are direct targets of NF-κB. NF-
κB pathways can be classified into canonical, non-canonical and atypical based on the different 
NF-κB dimers formed during activation 85. Most studies thus far have focused on the activation 
of the canonical pathway. Surprisingly, the striking nuclear localization of NFKB2 rather than 
RELA in injured Sm22-/- carotid arteries and primary Sm22-/- VSMCs indicated that non-
canonical NF-κB pathways activation is predominant in our situation. However, this does not 
seem to fully agree with the fact that both canonical and non-canonical NF-κB pathways were 
activated in PAC1 cells after Sm22 knockdown. There are several possible explanations for this 
discrepancy. One is that the injured carotid arteries were examined 2 weeks after injury, that is, 
outside the time window of acute inflammation, when the RELA-associated canonical pathway 
is activated in response to arterial injury 58, 92.  However, this cannot explain why the canonical 
pathway was activated in the Sm22 knockdown PAC1 cells, but not in the Sm22-/- primary 
VSMCs under the same culture condition. This discrepancy may be due to different 
differentiation states of primary VSMCs compared to the PAC1 VSMC cell line and response 
variations among different systems. PAC1 cells after Sm22 knockdown may more closely 
resemble an acute inflammation model, since our experiments were performed three days after 
transfection. In view of this, it would not surprise us to observe activation of NFKB2, the non-
canonic pathway, in the acute phase of carotid injury. This possibility could be examined in 
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future studies. Although it is possible that some of the NF-κB signals in injured arteries were 
from the infiltrated inflammatory cells, the in vitro NF-κB activation in VSMCs after Sm22 
disruption lends support to the possibility of in vivo NF-κB activation in VSMCs after carotid 
injury.  
 
NF-κB is a redox-sensitive transcription factor 86, 93, and ROS is one key source for NF-
κB activation in VSMCs in arterial diseases 42, 44, 93. On the other hand, increased ROS 
production under hypoxia 94 during osteochondral organogenesis activates ROS sensitive 
transcription machinery including HIF1A and contributes to transactivation of Sox9 75, 95. 
Although ROS production is associated with the hypoxia during embryogenic chondrogenesis, 
ROS is also generated under numerous non-hypoxic conditions 95, 96 and the hypoxia-
independent ROS in stressed VSMCs 87, 97, 98 may contribute to arterial calcification. Taken 
together, it is reasonable to propose that ROS might stand upstream of NF-κB activation after 
Sm22 knockdown in PAC1 cells and participate in the up-regulation of pro-inflammatory genes 
and Sox9. As expected, increased ROS level was disclosed in primary Sm22-/- VSMCs and in 
PAC1 after Sm22 knockdown indicating high oxidative stress in VSMCs with Sm22 disruption. 
Different ROS scavengers, Tiron, Tempol or NAC consistently blocked NF-κB activation and 
pro-inflammatory genes induction. This provides further evidence indicating that increased 
production of ROS may initiate NF-κB activation in PAC1 cells after Sm22 disruption.  We tried 
to identify increased ROS production in injured carotid arteries in vivo using both DHE and 
DCFDA on frozen sections. Disappointingly, high background from elastin and collagen 
thwarted further analysis. Although DHE and DCFDA-based assays have been used to detect 
ROS from live cells, ROS may not be preserved in our frozen sections. Nevertheless, we 
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observed higher expression of Sod2 in the injured Sm22-/- carotid arteries. Activated NF-κB 
perhaps induces Sod2 expression in anticipation of redox signaling. Therefore, increased 
expression of Sod2 may reflect a higher redox state in the injured carotid arteries of Sm22-/- mice. 
 
4.2. Sources of ROS production and association with cytoskeleton alteration 
Mitochondria and NADPH oxidase are two important sources of ROS in VSMCs 99, 100. 
The megamitochondria formation and mitochondria aggregation after Sm22 knockdown 
indicated mitochondria dysfunction associated with mitochondrial ROS production 89; the 
upregulated Sod2 may reflect such a dysfunction and serve as a rescuing mechanism via the 
ROS-NF-κB feedback (Fig. 30). NADPH oxidase, a major ROS source from VSMC membranes 
99, was also activated after Sm22 knockdown. These observations suggest that disruption of Sm22 
in stressed VSMCs may activate multiple ROS production mechanisms that might work together 
to foster a high redox environment.  
 
How does the disruption of an actin-binding protein lead to simultaneous activation of 
NADPH oxidase and dysfunction of mitochondria? Activation of NADPH oxidase requires the 
membrane assembly of cytosolic p47phox, p67phox, p40phox and Rac2 90, 99. It was reported 
that the actin cytoskeleton and associated proteins may affect this process 90. The correlation 
between NADPH oxidase activation and diminished stress fiber formation in PAC1 cells after 
Sm22 knockdown might reflect the role of the actin cytoskeleton in maintaining VSMCs 
phenotype. Furthermore, the actin cytoskeleton cooperates with microtubules 91 in regulating 
organelle distribution including mitochondria 91, 101. The mitochondria aggregation and formation 
of megamitochondria may be due to the compromised actin cytoskeleton after Sm22 knockdown 
  
78
or to be an outcome of subsequent disorganized microtubules. The changes in the fine structure 
of cytoskeleton and mitochondria after Sm22 disruption will be investigated in the future using 
electron microscopy. 
 
4.3. Arterial inflammation and arterial chondrogenesis: coupled or sequential? 
Accumulating studies indicate that inflammation participates in arterial 
osteochondrogenesis in a variety of arterial diseases 78. Indeed, our current study revealed 
prominent inflammation and enhanced medial chondrogenesis in injured carotid arteries from 
Sm22-/- mice. It is reasonable to argue that the enhanced chondrogenesis is caused by the 
exogenous cytokines from the infiltrated inflammatory cells such as macrophages. On the other 
hand, we can not exclude the possibility that loss of Sm22 autonomously couples chondrogenic 
conversion of VSMCs with inflammatory responses. This notion is supported by the following 
evidence. In Sm22 disrupted VSMCs, we observed the simultaneous activation of pro-
inflammatory NF-κB, Sox9 induction and the repression of myocardin. Since NF-κB can induce 
Sox9 expression 84 and repress myocardin myogenic activity 102, NF-κB may be pivotal in 
coupling chondrogenesis with inflammation in arterial diseases where Sm22 is down-regulated. 
Thus, it is noteworthy that this coupling of chondrogenesis and inflammation could be 
independent of inflammatory cells as reported before 52. Therefore, disruption of Sm22 in 
VSMCs might contribute to arterial osteochondrogenesis through at least two avenues, either 
directly by activating chondrogenic differentiation or indirectly by inducing pro-
osteochondrogenic events as a result of VSMC inflammation. 
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4.4. A working model for phenotypic modulation of VSMCs and arterial pathogenesis after 
Sm22 disruption 
Based on our in vivo and in vitro results, we propose that disruption of Sm22 expression 
in stressed VSMCs results in actin cytoskeleton and microtubules remodeling, thereby leading to 
a high redox state via mitochondria malfunction and NADPH oxidase activation. In turn, 
increased ROS production activates the NF-κB pathways required for establishing both pro-
inflammatory and chondrogenic/anti-myogenic environment (Fig. 30). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. A working model illustrating phenotypic modulation of VSMCs and arterial 
pathogenesis after Sm22 disruption. 
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4.5 Remarks on further research 
Questions of several layers remain to be answered. It is interesting to reveal that non-
canonical NF-κB pathway plays a pivotal role after Sm22 disruption; however, the specific NF-
κB complexes and the bridging pathways through which ROS activate NF-κB are yet to be 
characterized. Moreover, transcription factors function as modules, and NF-κB activation only 
samples the shifting patterns of global transcriptional network after Sm22 disruption. The 
dynamic map transcriptional regulatory machinery needs to be drawn in future research. To 
better understand how Sm22 exerts its effects on cytoskeletal organization and other molecular 
functions, domain mapping of Sm22 is an indispensable part of future research plan. Similarly 
important is the fact that Sm22-/- mice maintain arterial homeostasis equally well compared to 
their wild type littermates without pathogenic stimuli, which poses a possibility that VSMCs 
from these mice might have distinct stimulus sensing machinery (either more sensitive or more 
potent) that  remain inert in physiological conditions and only responds to arterial injury signals 
such as serum exposure. Thus, investigation on membrane receptors including GPCRs in these 
mice may hold key to another exciting discovery.  
 
Increasing evidence supports the notion that actin cytoskeleton remodeling plays 
important roles in VSMC phenotypic modulation 103. The present study on the consequences of 
abolishing Sm22, an actin-binding protein, offers a glimpse on how the cytoskeletal proteins 
could actively affect arterial pathogenesis. Therefore, maintaining VSMC cytoskeleton gene 
expression in VSMCs may serve as a therapeutic strategy to treat arterial diseases. One un-
addressed question is whether other VSMC cytoskeletal proteins also have similar anti-
inflammatory and anti-chondrogenic roles or these functions are unique to Sm22. Therefore, 
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paralleled research on other cytoskeletal proteins is anticipated. Given that carotid artery 
denudation is a simplified model for vascular injury, it is important to validate Sm22’s role as an 
anti-inflammatory agent in animal disease models such as diet-induced atherosclerosis mouse 
model. On the other hand, SM22 expression is downregulated in a variety of cancers 104. The 
finding that loss of Sm22 creates a pro-inflammatory environment may also shed lights on the 
role of downregulation of SM22 in carcinogenesis. Thus, maintaining SM22 expression might 
also serve as a therapeutic strategy to repress the dysregulated inflammatory responses in cancers.  
 
Particular Statement: the research results and text in this dissertation have 
been published 105, 106. 
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APPENDIX 
Appendix A: Abbreviations 
ACAN, aggrecan; 
ACTA2, smooth muscle α actin; 
ALP, alkaline phosphatase 
BGLAP, bone gamma-carboxyglutamic acid-containing protein, osteocalcin; 
CCL2, monocyte chemotactic protein 1;  
CD3, cluster of differentiation 3; 
CKD, chronic kidney disease; 
COL2A1, type II collagen α 1; 
Cre, Cre recombinase; 
CX3CL1, chemokine (C-X3-C motif) ligand 1;  
CXCL12, chemokine (C-X-C motif) ligand 12 
BMP2, bone morphogenic protein 2; 
DAB, diaminobenzidine; 
DAPI, 4',6-diamidino-2-phenylindole; 
DCFDA, dichloro fluorescein diacetate;  
DHE, dihydroethidium;  
DPI, diphenylene iodonium 
ECM, extracellular matrix; 
EMSA, electrophoresis migration shift assay;  
FBS, fetal bovine serum; 
G/F – actin, globular actin /filamentous actin; 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; 
H&E, hematoxylin and eosin stain; 
HIF1A, hypoxia-inducible factor 1, alpha subunit; 
ICAM1, intercellular adhesion molecule 1;  
IF, immunofluorescence;  
IHC, immunohistochemistry;  
IKB, I-kappa-B; 
IKK, IκB kinase; 
MGP, matrix gla protein; 
MYH11, smooth muscle myosin heavy chain; 
MYOCD, myocardin; 
NAC, N-Acetylcysteine; 
NADPH, reduced form of nicotinamide adenine dinucleotide phosphate; 
NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; 
NFKB1, p50; 
NFKB2, p52; 
OCT, optimal cutting temperature compound; 
p40phox, neutrophil cytosol factor 4; 
p47phox, neutrophil cytosol factor 1; 
p67phox, neutrophil cytosol factor 2; 
PAC1, a pulmonary arterial SMC cell line; 
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RAC2, Ras-related C3 botulinum toxin substrate 2 
rtRT-PCR, real-time RT-PCR;  
RUNX2, Runt-related transcription factor 2 
PTGS2, prostaglandin-endoperoxide synthase 2;  
RELA, p65; 
ROS, reactive oxygen species;  
siRNA, small interfering RNA;  
Sm22-/-, Sm22 knockout;  
Sm22+/+, Sm22 wild type;  
SMA, smooth muscle α actin; 
SMC, smooth muscle cell; 
snRNA, small nuclear RNA; 
SOD2, superoxide dismutase 2; 
SOX9, SRY-box containing gene 9; 
SPP1, osteopontin; 
SRY, sex determining region Y; 
VCAM1, vascular cell adhesion molecule 1;  
VSMC, vascular smooth muscle cell;  
WB, western blotting. 
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Background: Expression of vascular smooth muscle cell (VSMC) cytoskeleton markers 
including SM22 is down-regulated in arterial diseases including atherosclerosis where 
inflammation and osteochondrogenesis are present. However, the role of this downregulation in 
arterial pathogenesis is unknown.  
Hypothesis: Downregulation of SM22 may actively contribute to arterial pathogenesis. 
Methods: Five Sm22 knockout (Sm22-/-) mice and their wild type littermates were subjected to 
carotid artery denudation, an artery injury model. Analyses were conducted on carotid arteries 2 
weeks after injury. Primary VSMCs were isolated from mouse aortas and investigated 
individually at passage 2 to 4. Sm22 knockdown was performed in triplicate using siRNA in a 
VSMC line, PAC1, followed by downstream experiments 3 days after transfection.  
Results: Sm22-/- mice developed both enhanced arterial inflammatory response and 
prominent medial chondrogenesis along with remarkable NF-κB activation compared to their 
wild-type littermates. The inflammation was evidenced by excessive artery swelling, 
macrophage infiltration and high induction of pro-inflammatory molecules including Vcam1, 
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Icam1, Cx3cl1, Ptgs2 and Ccl2. The medial chondrogenesis was characterized by augmented 
expression of type II collagen, aggrecan, osteopontin, Bmp2 and the key osteochondrogenic 
transcription factors Sox9. In accordance with the in vivo findings, expression of the 
aforementioned pro-inflammatory genes and Sox9 was up-regulated in Sm22-/- primary VSMCs 
and after Sm22 knockdown in PAC1 cells. Interestingly, Sm22 knockdown also led to NF-κB 
activation, and inhibition of NF-κB pathway reversed the up-regulation of both pro-inflammatory 
genes and Sox9. As an initiator of NF-κB activation, reactive oxygen species (ROS) production 
was boosted in Sm22-/- primary VSMCs and after Sm22 knockdown. ROS scavengers effectively 
blocked NF-κB activation and induction of both pro-inflammatory genes and Sox9 after Sm22 
knockdown. Further, the altered cell morphology and increased actin dynamics after Sm22 
knockdown might contribute to the elevated ROS.  
Conclusions: These findings suggest that loss of Sm22 in VSMCs coupled injury induced 
arterial inflammation with chondrogenesis in part via ROS induced NF-κB activation and that 
Sm22 plays both anti-inflammatory and anti-osteochondrogenic roles in arterial diseases partly 
by maintaining actin cytoskeleton integrity. 
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